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The biochemistry and biological functions of many RNA modifications 
remain elusive, especially in higher eukaryotes. 3-methylcytidine (m3C) is one 
kind of methylation modification located on certain tRNA species and 
hypothesized to affect translation.  
This thesis reports that human METTL2 proteins catalyse m3C formation at 
position 32 of threonine tRNAAGU and tRNAUGU isoacceptors in vitro and in 
vivo. LC-MS/MS analysis showed both human and mouse METTL2 
contribute to 35% - 40% of total cellular m3C formation, while reduction of 
methyltransferase-like 6 protein (METTL6), another paralog of METTL2, 
reduce m3C contents by 10% - 15%. METTL6 is found to interact with seryl-
tRNA synthetase (SARS) in an RNA dependent manner, suggesting serine 
tRNAs as potential METTL6 substrates. Reduction or deletion of Mettl2, 6 
lead to significant decrease in cell proliferation rate and global translation 
changes in several cancer cell lines. The reduction also elicit higher sensitivity 
to one alkylating agent, MMS, consistent with the published data in yeast. 
Phylogenic and structural analysis of tRNA 32-38 pair indicates a potential 
role of m3C in modulating the interaction between tRNA and the translation 
machinery. These studies support METTL2, 6 as RNA m3C methyltransferase 







 LIST OF TABLES 
Table 1-1 Examples for methyltransferase-like proteins ................................ 24 
Table 2-1 Resolving gel recipe...................................................................... 40 
Table 2-2 Stacking gel recipe ........................................................................ 41 
Table 2-3 10X Running Buffer ..................................................................... 42 
Table 2-4 1X Running Buffer ....................................................................... 42 
Table 2-5 1X Transfer Buffer ....................................................................... 42 
Table 2-6 Gel sandwich in transfer ............................................................... 43 
Table 2-7 5' end labelling of DNA probes for primer extension..................... 48 
Table 2-8 Oligos used for primer extension for human cytoplasmic and 
Mitochondria tRNAs .................................................................................... 48 
Table 2-9 In Vitro Transcription Reactions ................................................... 52 
Table 2-10 In vitro reconstitution of m3C ..................................................... 52 
Table 2-11 Sucrose stock solution ................................................................. 57 
Table 2-12 2X Resuspension Buffer (RSB) Recipe ....................................... 57 
Table 2-13 1x RSB with Cycloheximide ....................................................... 57 
Table 2-14 1X Lysis Buffer .......................................................................... 58 
Table 2-15 Oligos for cloing Renilla luciferase and Firefly luciferase ........... 62 
Table 2-16 Oligos for Codon Runs ............................................................... 62 
Table 3-1 mRNA transcripts identified as binding partners of METTL8 by 
PAR-CLIP .................................................................................................... 99 
Table 3-2 METTL2, 6, 8 protein complex identified by Flag-IP Mass Spec 105 
Table 3-3 Oligos for cloning Renilla luciferase and Firefly luciferase ......... 113 
Table 3-4 tRNA 32–38 base pairs frequency in three domains of life .......... 117 
x 
 
Table 3-5 Threonine tRNA 32–38 base pairs frequency in three domains of 
life .............................................................................................................. 118 
Table 3-6 Summary of each 32-38 pair in the Figure 3-20........................... 120 
Table 4-1 Threonine codon percentage Ranking (content >16%) in human 
mRNAs ...................................................................................................... 138 
Table 4-2 Potential functions of 3-methylcytosine in various Cellular 





 LIST OF FIGURES 
Figure 1-1 A schematic of tRNA numbering and modifications found in 
cytoplasmic tRNA in S. cerevisiae. ................................................................. 4 
Figure 1-2 Principles of Primer extension assay and examples ...................... 13 
Figure 1-3 Chemical structure of cytidine, 3-methylcytidine (m3C), and 
proposed mechanism for m3C formation ....................................................... 25 
Figure 1-4 m3C occurs at position 32 of several tRNA species ...................... 27 
Figure 3-1 Sequence alignment of the METTL2 with its paralogs and 
homologs ...................................................................................................... 70 
Figure 3-2 Subcellular localizations of METTL2, 6, 8 .................................. 72 
Figure 3-3 CRISPR/Cas9 mediated Mettl2A & 2B gene knockout in 293T 
cells .............................................................................................................. 76 
Figure 3-4 Purification of METTL2 by Affinity and Size Exclusion 
Chromatography ........................................................................................... 81 
Figure 3-5 Schematic diagram of human tRNAs and corresponding probes 
used in primer extension assay. ..................................................................... 82 
Figure 3-6 Loss of METTL2A & 2B abolished the modification at position 32 
in tRNAThrAGU and tRNAThr UGU isoacceptors .......................................... 84 
Figure 3-7 Reduction or loss of METTL2, 6 or 8 has no effects on the position 
32 modification in other tRNA species tested................................................ 85 
Figure 3-8 Ectopic expression METTL2 protein in KO cells restore the 
position 32 modification in tRNA ThrAGU and ThrUGU .................................. 86 
Figure 3-9 In Vitro reconstitution of modification on tRNA ThrAGU and  
ThrUGU by recombinant METTL2 ................................................................. 88 
xii 
 
Figure 3-10 METTL2B fail to restore position 32 modification on in vitro 
transcribed tRNA ThrAGU and ThrUGU. .......................................................... 89 
Figure 3-11 Quantitative PCR based assay for quantification of m3C (qPCR-
m3C) ............................................................................................................. 92 
Figure 3-12. Size exclusion HPLC and typical chromatography of LC-MS/MS 
for m3C ......................................................................................................... 97 
Figure 3-13. LC-MS/MS for quantitative m3C analysis in various RNA species
 ..................................................................................................................... 98 
Figure 3-14 Validation of METTL2, 8 RNA binding species identified by 
PAR-CLIP .................................................................................................. 101 
Figure 3-15 METTL2 could auto-methylate itself in vitro ........................... 103 
Figure 3-16 METTL6 interact with seryl-tRNA synthetase (SARS) in a RNA 
dependent manner ....................................................................................... 107 
Figure 3-17 METTL2, 6, 8 could affect global Translation ......................... 110 
Figure 3-18 Loss of METTL2, 6, 8 confers higher sensitivity to translation 
inhibitors and alkylation damages ............................................................... 112 
Figure 3-19 Codon-run to study effects of 3-methylcytosine on translation . 115 
Figure 3-20 Interaction between tRNA Residue 32 and 38 extracted from 
solved structures ......................................................................................... 120 
Figure 4-1 Methylation sites identified by mass spectrometry ..................... 127 
Figure 4-2 Nitrogen methyl group on polar contacts ................................... 131 
Figure 4-3 Enrichment of some codons and tRNA isoacceptors in Eukaryotics
 ................................................................................................................... 133 
Figure 4-4 Seryl-tRNA synthetase structures of T.Thermophilus and homo 
sapiens ....................................................................................................... 137 
xiii 
 
Figure 4-5 Model for possible roles of METTL2 in tRNA modification and 






 LIST OF SYMBOLS  
3mC or m3C 3-methylcytosine 
aa amino acid 
aaRS Amino Acyl-tRNA Synthetase 
aa-tRNA aminoacyl-tRNA 
ABP140 Actin-binding protein,140kDa 
Anota Analysis of translational activity 
APS Ammonium peroxodisulfate 
Arg Arginine 
ATP Adenosine 5’-triphosphate 
bp  base pairs 
BSA bovine serum albumin 
ChIP  chromatin immunoprecipitation 
CHX Cycloheximide 
Cm 2′-O-methylcytidine  
CRISPR clustered regularly interspaced short palindromic 
repeats 
DAPI  4', 6-diamidino-2-phenylindole 
DMSO  dimethyl sulfoxide 
DSB  double-strand break 
dsDNA  double-stranded DNA 
E.coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
FBS Fetal Bovine Serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
gDNA genomic DNA 
GFP  green fluorescent protein 
Glu glutamic acid 




HEPES  N-2-hydroxyethylpiperazine-N-2-ethane sulfonic 
acid 
hMETTL2A, 2B, 6, 8 Human Methyltransferase-like Protein 2A, 2B, 6 
and 8  
HRP  horseradish peroxidase 
IB immunoblotting 
IgG  immunoglobulin g 
IP immunoprecipitation 
IR irradiation 
kb  kilobases 
KCl potassium chloride 
KD  Knockdown 
kDa kilodalton 
KO Knockout  
LB  Luria-Bertani medium 
m1A 1-methyladenosine  
m2,2G N2,N2-dimethylguanosine  
M2/Mettl2 methyltransferase like protein 2 
m7G 7-methylguanosine  
Mass Spec Mass Spectrometry 
MEF Mouse embryonic fibroblast 
MMS Methyl Methanesulfonate 
mRNA  messenger RNA 
MTase Methyltransferase 
Neo Neomycin 
Ni column affinity column with nickel  
NP-40  Tergitol-type NP-40 
nt nucleotide 
OD  Optical density 
PAGE  polyacrylamide gel electrophoresis 
PAR-CLIP Photoactivatable-Ribonucleoside-Enhanced 
Crosslinking and Immunoprecipitation 
xvi 
 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
Puro puromycin 
qPCR Quantitative Real-Time PCR 
Riso-seq  Ribosome profiling 
rRNA ribosomal RNA 
RSB Resuspension Buffer 
RT-PCR Reverse transcription-PCR 
SAM S-adenosylmethionine 
SARS Seryl-tRNA synthetase 
SDS  sodium dodecyl sulfate 
Ser Serine 
ssDNA  single-stranded DNA 
ssRNA single-stranded RNA 
TE  Tris-EDTA buffer 
TEMED Tetramethylethyl 
Thr Threonine 
Tris  Tris(hydroxymethyl)aminomethane 
TRM140 ABP140/tRNA Methyltransferase, 140kDa 
tRNA transfer RNA 
UTR untranslated region 







1 CHAPTER 1. INTRODUCTION 
1.1 The importance of being modified: diversity and prevalence of RNA 
modifications 
Naturally occurring DNA or RNA polymers were once thought to consist of 
only four canonical nucleosides A, T, C, G or A, U, C, G respectively. The 
presence of trace amount of non-canonical nucleoside in DNA was reported in 
1948(1) and this nucleoside was identified as 5-methylcytosine in 1950 (2) 
and later became one of the focuses in epigenetic research together with 6-
methyladenosine, histone modifications, etc. It was then found in 1951 that 
RNA also contains small but significant amount of non-canonical nucleosides 
(3) and it is determined to be 5-ribosyluracil, an isomer towards the canonical 
1-ribosyluracil or uridine (4), also named the fifth base in RNA or 
pseudouridine (Ψ) later. A great enthusiasm has been kept for discovering 
other thought minor or rare nucleosides in RNA or DNA polymers since then. 
For example, inosine was identified by Holley's lab at the first position of the 
anticodon of yeast tRNA Ala(5) and were quickly adapted by Crick's Wobble 
Hypothesis(6). Today the count of naturally occurring modified nucleosides is 
114 according to Modomics (7). The number increases to 141 if residues that 
are doubly modified are included, like those containing a modified base and a 
methylation on the ribose, and there are approximately 50 modifications in 
mammalians (7).  
Those naturally occurring modifications are found in three major RNA species 
(tRNA, rRNA and mRNA) and some other minor RNA species, such as 
snRNA, miRNA and lncRNA, in Archaea, Bacteria and Eukarya. Although 
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different modifications show significant differences in abundance and site 
preference in various RNA species (7). These modified nucleosides are 
formed during maturation of nascent precursor RNA transcripts, or so called 
post-transcriptional modification or co-transcriptional modification, catalysed 
by modification enzymes in one step or several steps. 
In general, the inherent ability of RNA is reinforced through the site selected 
installation of over 100 post-transcriptional modifications (7). However, their 
effects can be subtle and not easy to demonstrate either in vivo or in vitro. 
What’s more, the investigation of modification enzymes was once limited by 
the presence of these enzymes in small cellular amounts, making them 
difficult to detect, let alone purify in sufficient amounts for enzymatic 
characterization before recombinant proteins are utilized for large scale 
purification. Additionally, the functional relevance of RNA modified was 
unclear because the genes coding for modification enzymes could be 
genetically deleted with only subtle or non-detectable effect on cell growth. 
Fortunately, interest in this research was sustained by the demonstration of a 
functional importance of several modified nucleotides in the anticodon loop of 
tRNA, namely the wobble nucleotide (position 34) and the nucleotide 
(position 37) that is next to the third anticodon nucleotide. Modifications at 
these sites correlate with clear-cut increases in the efficacy and accuracy of 
translation, a process that is termed translational fine-tuning. Moreover, RNA 
modifications have much more functions and will be discussed below. 
Nevertheless, remarkable progress has been achieved in understanding 
functions these modifications in RNA after years of investigation since the 
discovery of Ψ in RNA. In fact,  modifications on RNA are one of the most 
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conserved properties. Here, RNA modification occurs in different RNA 
species will be briefly reviewed (notice one modification could occur in 
different RNA species), followed by characteristics of a few modified 
nucleosides and their corresponding enzymes, finalized by discussing one of 
the most simple, but important modification: methylation and their 
methyltransferases.  
1.1.1 RNA modification in tRNA 
tRNA is the most entensively modified RNA species (8). As shown in Figure 
1-1, the reason why tRNA is so heavily modified is still elusive. These 
modifications are hypothesized or proven to elicit various functions, including 
affecting translation rates, fidelity, tRNA stability, tRNA discrimination, etc. 
For example,  It was shown the absence of inosine at wobble position 34 could 
generate coding errors, since inosine would extends anticodon-codon pairing 
capability through base pairing with U, A, and C, while A can only pairs with 
U. tRNA modification may increase tRNA half-life, which is relatively long, 
with estimates of 44 h in Euglena gracilis, 50 h in chicken muscle, and 3 d in 
avian liver (9-11), roughly comparable with the half-life of rRNA(10, 11). 
m1A58 on tRNAiMet is required for its stability(12), while Dnmt2 and Nsun2 
are required for certain tRNA’s stability(13). Longer half-life means more 
tRNA reuse and it would be regarded as a way of energy saving instead of de 
novo tRNA synthesis by transcription.  In other words, modifications allow 
cells to respond to signals without the need for additional transcription. More 
evidence are showing modifications are temporally more responsive than the 
transcription apparatus, and result in conformational diversity, and population 
heterogeneity. The modified nucleosides are not recognized by native RNA 
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polymerases in vivo, offering a more flexible path for modification as a 
dynamic and regulatory mechanism.  Moreover, initiator tRNAMet is 
distinguished from elongator tRNAMet through ribosylation at position A64 
(12).  The review below will focus on several tRNA modifications, and on 
how they offer advantage in its conformation and interaction with the 
translation apparatus. 
 
Figure 1-1 A schematic of tRNA numbering and modifications found in 
cytoplasmic tRNA in S. cerevisiae. 
Adapted from figure 1 of (14). tRNA is shown in its usual secondary cover 
leaf structure form; Green circles are Residues that are unmodified in all yeast 
tRNA species; Pink circles are residues that are modified in some or all tRNA 
species; White circles are additional residues (20a and 20b) that are present in 
some, but not all, tRNAs and are sometimes modified; Red circles are 
anticodon residues, which are modified in some tRNAs; Blue circles are the 
CCA end. Conventional abbreviations are used; see the Modomics database 
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(http://modomics.genesilico.pl). For example: 2′-O-methylcytidine (Cm), 
N2,N2-dimethylguanosine (m2,2G), 3-methylcytidine (m3C). The pictured 
molecule starts at position -1 and is numbered consecutively from the next 
base (+1) to 76, with the insertion of two residues 20a and 20b. Several tRNA 
species, such as serine tRNA in cytoplasm have a longer variable arm starting 
after residue 44, and some tRNAs have different numbers of residues in the D-
loop and the variable arm, but the anticodon is always numbered residues 34, 
35, and 36, and the CCA end is always numbered residues 74, 75, and 76. 
 
1.1.2 RNA modification in rRNA 
rRNA modifications are generally located in functional regions such as 
peptidyl transferase center (PTC), the A, P and E sites for tRNA and mRNA 
binding, the polypeptide exit tunnel, and sites of subunits interaction(15). 
These correlations suggest that nucleotide modifications are key to many 
rRNA functions. The long term hypothesis for the function of rRNA 
modifications is that they could modulate the ribosome’s structures and 
functions and foster maturation. For instance, two most abundant modification 
in rRNA, Ψ and 2’-O-methyl ,could stabilize RNA base stacking (16) and 
prevents phosphate backbone hydrolysis by many ribonuclease (17), 
respectively. There are currently over 90 pseudouridines (Ψ) and over 100 2’ 
O-methylations on ribose and over 10 base methylations on human ribosomes 
(18). Although individual rRNA modifications is dispensable to some degree, 
they are indispensable when considered jointly. For instance, loss of certain 
rRNA modifications at peptidyl transfer centre will display decreased near-
cognate tRNAs’ discrimination capacity, reduced peptidyl transfer speed, 
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translation fidelity, and higher sensitivity to drugs targeting translation 
machinery. The exact abundance, and dynamics on ribosome rRNA 
modifications still require further investigation for possible usage in synthetic 
biology, such as synthetic ribosomes.  
1.1.3 RNA modification in mRNA 
Although less abundant, there are several modifications found on messenger 
RNAs. In mammalians, m7G is added towards the 5’ end of mRNA, which is a 
critical step from precursor messenger RNA to mature messenger RNA. This 
cap is important in splicing, mRNA nuclear export, and it is crucial during 
translation initiation (19). Meanwhile, m6A, Ψ, m5C, I and 2’O methylation of 
ribose were found to be localized at the internal body of mRNA. Recently, 
m1A have been found as a new methyl mark on mRNA, mainly cluster at 
starting codons and hypothesized to affect translation (20, 21) . 
mRNA modifications located in coding sequence need to be non-mutagenic, 
otherwise they will not preserve the genetic information from DNA. It is 
maybe the reason why most nucleoside modifications on mRNA are 
methylations (7), which minimize the disturbance towards the mRNA.  
The N6-methyladenosine (m6A) is the most frequent internal modification in 
eukaryotic mRNA. It was first discovered together with 5’ G cap in 1970s (22, 
23). It has been shown that m6A mainly localize within a G (m6A) C (Approx. 
70%) or A (m6A) C (approx. 30%) consensus sequence. A large protein 
complex is found to install s this methylation and it turns out to contain Mettl3, 
Mettl14 and a splicing regulator, WTAP, (24, 25), However, due to large 
molecular weight of the complex (Approx.1000kDa), other proteins/co-factors 
which are partners to the enzymatic core remain to be identified. For 
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biological functions, m6A is critical for yeast meiosis(26), required for Notch 
signalling during oogenesis in fruit fly (27), plant development (28), and to be 
essential for self-renewal of mammalian embryonic stem cells (29). 
Although C5-Methylcytosine is the mostly known for its role in eukaryotic 
genomic DNA, it is also of relatively high abundance in rRNAs and tRNAs. 
More than 10,000 possible m5C sites in mRNA and noncoding RNAs is 
reaved by a transcriptome-wide mapping (30). UTR and regions around 
Argonaute binding sites are enriched from m5C, and several sites were 
confirmed in using either anti-m5C immunoprecipitation coupled with next 
generation sequencing or RNA bisulfite sequencing. Some sites on mRNA are 
found to be bound by several m5C MTase targeting rRNA or tRNA, 
suggesting potential undiscovered mRNA substrates. There is a possible role 
of  m5C metabolic processes since several genes harbouring m5C are found to 
be involved in those pathways (31). But the role of m5C in RNA largely 
remains to be elucidated. 
1.1.4 RNA modification in other RNA species 
Long non-coding RNA (lncRNA) are found to be involved in many cellular 
processes, such as chromosomal remodelling, transcription, X-inactivation an 
imprinting(32). It has been shown that some lncRNAs, such as NEAT1, 
MALAT1, contain multiple m6A sites (33-35) with poorly known functions. 
Another non-coding RNA species, Small nuclear RNAs ( snRNAs ), the RNA 
parts of the spliceosome,  also harbours a couple of internal modifications 
such as Ψ, 2’ O-methylation and m6A without knowing specific functions in 
snRNA besides the known general functions. 
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1.1.5 Some other common modifications 
Pseudouridine (Ψ) : Pseudourindine is also named the 5th base, was the first 
found RNA modification identified in the 1950s (36). Isomerization allows the 
potential formation of an additional hydrogen bond which can affect the RNA 
3D structure of RNA drastically. The presence of Ψ l on mRNA could fine-
tune translation by employing Ψ reader proteins or altering the secondary 
structures of mRNA. Changing the first uridine residue on the stop codon to Ψ 
can turn nonsense codon to sense codon (37). This finding expanded the 
genetic code,  or in other words, it showed RNA modifications on mRNA 
could make transcripts recoded (37). Recently, hundreds of Ψ sites has been 
mapped in a transcriptome wide manner on yeast and human mRNA. These Ψ 
sites dynamic upon nutrition starvation or heat-shock (38, 39), suggesting 
introducing Ψ modification as a possible mechanism to adapt the translatome 
speedily to various environmental stress. 
Inosine (I) : Inosine was identified by Holley's group at the 1st  position at 
anticodon of yeast tRNAAla in 1965 and it is the second example of modified 
nucleotide in RNA after pseudouridine (40). It was quickly adapted by Crick's 
Wobble Hypothesis in 1966 (6). The A to I deamination at Wobble position at 
tRNAs’ anticodon enables tRNA to read three synonymous codons: NNA, 
NNU and NNC (N for any nucleotides). Wobble at the third position of the 
anticodon together with other chemistry and structures caused by other 
modifications enable some 40 cytoplasmic tRNAs to translate the 61 Universal 




The non-canonical A - I base pair raised the question of how a purine- purine 
interaction is accommodated at the decoding site on the ribosome and it was 
answered with ribosome co-crystallized with tRNA. It was showed that the 
decoding site accommodates the distorted anticodon-codon double helix of A - 
I and the extensively modified anticodon -codon base pairs (41).  Moreover, 
Paul Agris’s lab demonstrated that 2-thiocytidine occurring in the anticodon 
loop of the isoaccepting tRNAArg1 species negates inosine's ability to read 
adenosine while allowing the recognition of U and C. Thus, sometimes 
multiple modifications that occur close in space work together to affect RNA 
dynamics conformations and function.  
2’-O-Methylation 
2’-O-methylation occurs on the ribose and will protect RNA from cleavages 
by certain kinds of  endonuclease. It has been synthesized into small 
interference RNA (siRNA) to improve the stability and avoid inflammatory 
signals during knocking down experiments (42) since 2’-O-methylation has a 
role in discrimination between self and non-self mRNA. Abolishment of 2’-O-
methylation in human or mice coronavirus will trigger type I interferon 
response via the recognition by a RIG-I-like receptor, MDA5, which could 
binds dsRNA. 2’ O-methylation catalysed by a MTase HEN1 is naturally 
present in Plant microRNAs. The function of such a modification is suggested 
to protect the 3’ end of miRNA against poly-uridylation mediated degradation. 
1.1.6 Modifications resembles the side chains of amino acids 
RNA's modified nucleosides are more than simple modulators of structure and 
function. The genetic information, material consumption, and energy used in 
producing modified nucleosides by all organisms has evolved into a conserved 
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and ubiquitous investment. The chemistries of RNA modifications and their 
effects on structure seem similar to amino acid’s side chains, either 
hydrophilic, polar and charged, and hydrophobic, aliphatic and aromatic. 10 
physicochemical properties of modification chemistry, including spatial 
effects were attributed to their functions, as initiated by Paul Agris as early as 
1996 (43).  
Modification directs the RNA into the conformation most needed for the task 
at hand, whether that be tRNA, rRNA, snRNAs, mRNAs or miRNAs or 
lncRNAs. The sequences of the ribosome's peptidyl transferase site differ 
among organisms, but modifications are found conserved within the functional 
structure. The positions of pseudouridines and 2’-O-methylations in many 
types of RNA, rRNAs, snRNAs, from different organisms are conserved. 
These most ubiquitous of modifications are often found to facilitate RNA 
folding, structure, and conformational dynamics.  
The modified wobble hypothesis presented in 1991 invoked the chemical and 
structural contributions of modified nucleosides to account for tRNA being 
either constrained in its codon recognition, or relaxed in its abilities to read 
multiple codons. Modified nucleoside prestructure RNA for function. The 
prestructuring lowers energy barriers to RNA/RNA and RNA/protein 
interactions. The fact that many modification enzymes are at the ready when 
RNA is transcribed makes one wonder whether the modification of any RNA 
can be an immediate temporal response to internal and external signals in a 
time frame shorter than that of gene expression. While RNA is inherently 
transient, we now know that some modifications are even more so with the 
discovery of demethylations.  
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1.1.7 Modifications represent an additional, operational code, a third 
code 
The Universal Genetic Code provided insight into the decoding of genes, 
while Nucleosides proximal to tRNA's 3’- aminoacyl-terminus, including the 
discriminator nucleotide (position 73), are recognition determinants for 
aminoacylation and as such are a second code discovered by Paul Schimmel. 
RNA modifications as determiners of functional structure, indicators of 
cellular function and health and a distinctive set of biomarkers for health and 
disease, are a third code. The field are gaining insights into this code with 
improvements in analytical sensitivity and high throughput methods that relate 
modified nucleoside chemistry and structure to cellular function and human 
health issues. 
 
1.2 Detection and quantification of RNA modifications 
The difficulty in detecting the usual low abundance of RNA modifications is 
still a bottleneck in the field. Currently, enzymatic detection such as Reverse 
transcription-based methods, detection based on differences in 
physicochemical properties or chemical reactivity of different modifications 
are three major principles for the detection and quantification of RNA 
modifications(44), and will be discussed below.  
1.2.1 Detection of RNA modifications by different enzymatic behaviors 
Arrest of primer extension during reverse transcription  
It may result in different enzymatic reaction efficiency when cellular enzymes 
encounters a nucleosides with modification. Such different behaviours could 
be exploited for detection. One notable example is reverse transcriptase, which 
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may stall when meet certain modification in the RNA template. In general, 
modifications on the Watson-Crick edge of the nucleosides such as m3C, 
which is the focus of the thesis, and m1A, m3U, m22G, m1G are likely to stop 
the incorporation of a complementary nucleotide. 2'-OMe modification, which 
occurs at the ribose, could also present a hard stop for reverse transcriptase.  
Chemically small modifications, such as Ψ, m5U, m5C, m2G usually didn’t 
stall the reverse transcription if located on the Hoogsteen edge. For bulky 
modifications at the Hoogsteen edge, the experimental conditions, such as the 
concentration of dNTPs or reaction temperatures affects the read-through (45). 
Generation a hard stop which could block/stall reverse transcription by certain 
chemicals, followed by comparing WT or KO samples by second generation 
sequencing present the most cutting edge methods for certain modification 
detection. For example, Ψ and m5C has been mapped at transcriptome level 
by treating with CMC, and bisulfides, respectively and followed by second 




Figure 1-2 Principles of Primer extension assay and examples 
Adapted from (47) 
(A) Principles of primer extension assay, chemical structure of 1-
methyladenosine and 3-methylcytidine is shown at the top panel; Reverse 
transcription would be blocked when reverse transcriptase meet certain 
modified nucleotide; 
(B) Diagram of tRNAThr IGU showing the localization of m3C  
(C) tRNAThr IGU was purified from WT cells and incubated with demethylase 
AlkB from E. Coli, and assayed by primer extension, showing the abolishment 
of extension block  
(D) Primer extension block is abolished using tRNA from ABP140 KO strain  
Ligation-based approach (restricted to Ψ, m6A and 2'-OMe) 
Recently, an approach based on splint ligation  has been developed(48). 
However, this methods are restricted to Ψ, m6 A and 2'-OMe so far. 
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Restriction enzyme-based sequencing (restricted to m6A and m5C) 
Restriction enzyme-based sequencing, e.g.6mA-REseq, relies on the 
identification of restriction enzymes with respective recognition sites and the 
sensitivity to the corresponding DNA modification (49). For 6mA-REseq, 
genomic DNA is digested with a 6mA-sensitive enzyme and randomly sheared, 
which results in an enrichment of unmethylated sequence motifs at the ends of 
the sequencing reads. In contrast, 6-methylated adenine prevents digestion and 
is enriched in inner body of the reads. Consequently, 6mA levels are readily 
inferred from the relative positions of the restriction enzyme consensus 
sequence (49, 50). 
Single-Molecule Real-Time Sequencing (SMRT) 
Genome wide 6-methyladenine locations at base-pair resolution were obtained 
in E. coli genomes using single-molecule real-time (SMRT) sequencing (51, 
52). SMRT, a third-generation sequencing technique, is based on the 
processing of fluorescence-labeled nucleotides by DNA polymerases. The 
fluorescence label is not incorporated in the de novo synthesized strand but is 
cleaved away during the process. Meanwhile, the label emits light that is 
captured in the nanophotonic visualization chamber. High-fidelity 
polymerases are capable of synthesizing long continuous strands at a high 
speed, allowing a fast sequencing process and high read lengths. Importantly, 
the incorporation of a modified nucleotide, such as 6mA, presents different 
kinetics compared with unmodified adenine, allowing the direct inference of 
the modification status of each base. 
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1.2.2 Detection of RNA modifications by different physicochemical 
properties 
Most of the modifications are just minor decorations on the RNA, compared 
with the major sugar and base of RNA. A modified RNA cannot be easily 
distinguished from its unmodified form since a small modification such as 
adding a methyl group elicit minor changes to the RNA’s properties.  
Most of the HPLC/LC/MS/MS would digest the RNA polymers by nuclease 
and phosphatase. Modifications are identified by their retention characteristics 
in chromatography and capillary electrophoresis, or by their characteristic 
mass-to-charge ratio (m/z), respectively. 
Thin layer chromatography (TLC) is once the predominant way for the 
detection and identification of modifications. Although the Rf values of over 
100 modified nucleotides or dinucleotides have been mapped in standard 
solvent systems, the technique is not commonly used after the advent of mass 
spec. 
Liquid chromatography (LC) coupled with UV is still common in nucleoside 
detection. A comprehensive work on adapting different LC-UV methods to 
separate 65 nucleosides in a single run and identification via retention time 
and UV spectrum is given by(53).  
Ultra-high performance liquid chromatography-triple quadrupole mass 
spectrometry coupled with multiple-reaction monitoring (UHPLC-MRM-
MS/MS) allows the sensitive detection of nucleotide modifications, such as 
5mC, 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) at very low 
abundance (54). It has been modified to detect low abundance m6A in 
C.elegants(55), Drosphila(56) and Chlamydomonas(49) recently. Briefly, the 
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digested DNA is separated by reverse-phase ultra-high performance liquid 
chromatography (UHPLC) coupled with mass spectrometry detection using 
tandem mass spectrometers (MS/MS). Following detection of specific 
nucleotide modifications, quantification is achieved using a standard curve 
that is simultaneously analysed in the sample of interest. It is important to 
discard any potential contamination from Mycoplasma or bacterial DNA. 
1.2.3 Detection of  RNA modifications by different chemical reactivity 
Knowledge on different chemical reactivity towards a variety of chemical 
between canonical or modified nucleotides is accumulated through years by 
biochemists and is a chest of treasure for detecting modifications. An 
important discovery from the 1970s along with the development of Maxam & 
Gilbert DNA/RNA sequencing method is the different sensitivity of certain 
modified nucleotides towards aniline induced chain scission via β-
elimination(57). For example, m7G requires pre-treatment with NaBH4, while 
3-methylcytosine (m3C) should be treated with hydrazine to allow chain 
scission. The latter reactions are actually one of the basis of direct DNA/RNA 
sequencing by the Maxam & Gilbert. As discussed earlier, the low abundant 
occurrence of modifications makes the application of physicochemical 
techniques such as HPLC/MS challenging. Chemical treatments towards 
different modifications offer advantages include tagging modifications for 
improved detection by other means, such as biotin, or adapting high 
throughput methods for the detection of modifications on a genome wide scale 
with reverse transcription based RNA seq.  
Reagents which could selectively react with modified nucleotides only in a 
narrow window of well-defined experimental conditions have been identified 
17 
 
(58-60).  Taking pseudouridines (Ψ) as an example, there are at least 4 
different chemicals that have been utilized to treat and detect Ψ (61). CMCT 
acylates G, U, inosine and Ψ residues under physiological conditions and 
alkaline treatment could leave only N3-acylated pseudouridines intact. The 
latter could arrest reverse transcription and can thus be detected by primer 
extension techniques similar and has been recently adapted towards 
identifying pseudouridines at whole transcriptome level (38, 39). Many other 
modifications could be chemically treated by different reagents and proceed to 
RT based RNA-seq profiling. 
1.2.4 Antibody based detection followed by second generation 
sequencing  
Producing antibodies targeting modified nucleosides have been performed as 
early as 1970s for inosine (62). Antibodies against m5C m6A for either DNA 
or RNA has been generated to be able to perform immunoprecipitation 
coupled with next-generation sequencing to identify of those modifications at 
genome wide(33, 34, 63). For example, 6mA-immunoprecipitation sequencing 
(6mA-IPseq) utilizes a specific antibody for 6-methyladenine to enrich 
modified fragments from the sequencing library. Following the alignment of 
sequencing reads to the reference genome, 6mA-modified regions present 
enriched mapping frequencies. Subsequent sequence enrichment analysis can 
reveal consensus recognition motifs for the adenine methyltransferases. 
However, the immunoprecipitation based identification of modification 
genome wide or in whole transcriptome has only been developed for a limit 
number of modifications in general. A number of attempts on generating 
antibodies against modified ribonucleoside such as Ψ, m5C, m1A, m2,2G, 
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m1G, m7G, m1I, i6A,and ac4C seems to be ceased by the late 1990s(64-71), 
probably due to the low abundance of certain modifications and the 
improvements in Mass Spec sensitivity. Antibody against m3C in DNA has 
also been raised to use only in dot blot(72).  
 
1.3 Identification of enzymes responsible for specific RNA modifications 
RNA modifications are carried out by specific enzymes. The identification and 
purification of RNA modifying enzymes for medium to low occurrence 
modifications were challenging tasks. The main obstacles includes the 
difficulty in obtaining pure individual RNA species as substrate, the presence 
of endogenous RNases, the typically low abundance of the enzymes involved 
in RNA modification, etc. Determining the presence or absence of the specific 
modified nucleotides, which is not an easy task before the advent of UHPLC 
and capable Mass Spectrometry as discussed in section 1.2.  Nevertheless, a 
couple of enzymes are identified and characterized by using classic 
biochemical and genetic approaches such as using standard chromatographic 
techniques(73).  
Fortunately, recent developments of the recombinant DNA and RNA 
technologies, together with techniques for chemical synthesis of DNA and 
RNA and detection of modified nucleosides in nucleic acids using Mass 
spectrometry(74) offers possibilities to obtain synthetic or semi-synthetic 
substrates. Subsequently, it is then possible to analyze the modified nucleoside 
content after incubation with cell extracts. Moreover “classical” biochemical 
and genetic methods for identification of new RNA MTases can be efficiently 
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supplemented by “reverse genetics” and large-scale “-omics” approaches, 
including biochemical genomics.  
Comparative genomics has been shown useful to identify the responsible 
genes, as is the case for 5,6-dihydrouridine synthase which is one of the most 
common and abundant modifications on tRNAs (75), and is also present in 
some 23S RNA(76), but both the genes and enzymes in many organisms were 
unknown. By combining occurrence, chromosome localizations, and 
homologue searches, the Dus family of genes that contains orthologues in 
most sequenced species was identified(75). The last decade has witnessed 
great progress in the identification of the genes and corresponding enzymes 
that are required for modification, as well as in our understanding of their 
biochemistry and their biological roles. Thus, in S. cerevisiae, the vast 
majority of the genes that are responsible for modifications have now been 
identified, and a large number of modification genes and enzymes have been 
identified in other organisms (see the Modomics database, 
http://modomics.genesilico.pl). 
1.4 Methylation and methyltransferase (MTase) 
Methyltransferase is a subclass of transferase class enzymes that catalyze the 
transfer of a methyl group from one compound to another. There are currently 
over 300 types of Transmethylation reactions that are designated under 
Enzyme Commission 2.2.1: Methyltransferases. S-Adenosylmethionine (SAM 
or S-AdoMet) was used by the majority of methyltransferase as methyl group 
donors or co-factors in a transmethylation reaction, in which SAM donates its 
methyl-group towards a variety of substrates including macromolecules such 
as nucleic acids, proteins, lipids and secondary small metabolites such as 
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glycine, nicotinamide, indolethylamine, phenylethanolamine, etc, and the 
atomic targets could be C, N, O, S, halide ions, or As-cantered nucleophiles. 
SAM was first discovered in 1952 as a conjugate of methionine and the 
adenosine moiety of ATP(77, 78). It is the second most widely used enzyme 
substrates following ATP, involving in a variety of metabolic pathways such 
as transmethylation, transsulfuration, and aminopropylation(79).  Most 
transmethylation reactions catalyzed by SAM-dependent MTases are 
bimolecular nucleophilic substitution (SN2) reactions, in which one bond is 
broken and one bond is formed synchronously, generating S-adenosyl-
homocysteine (SAH or AdoHcy) as the by-product. SAM-dependent MTase 
are inhibited by the product SAH, which can accumulate in the presence of 
homocysteine because the equilibrium of the SAH hydrolase reaction favors 
SAH formation (80).  
1.4.1 Structural features of MTase  
The structural and catalytic mechanism for methyltransfer reactions could be  
remarkably diverse since they could share little amino acid sequence similarity 
but adopted highly conserved structural folds (81). There are currently five 
designated families of SAM-dependent MTases ( from Classes I to V) based 
on their distinct structural features with Class I being the great majority(82). 
Another class of radical SAM-dependent MTases that methylate a range of 
substrates at unreactive, non-nucleophilic carbon and phosphorus centers was 
recently discovered (83).   
Class I MTases with the Rossmann fold are the largest group of MTases, 
responsible for the majority of transmethylation. Structure of Class I MTases 
are strikingly similar, usually comprising a 7 stranded β sheets with a 
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structural turning point and a signature reversed β hairpin at the C terminal 
(represented as 6 ↑ 7 ↓ 5 ↑ 4 ↑ 1 ↑ 2 ↑ 3 ↑) The first β sheet usually ends up 
with GxGxG motif which is a signature for nucleotide binding. The only other 
strongly conserved position is an acidic residue at the end of β2 that forms 
hydrogen bonds to both hydroxyls located on the sugar part of SAM(84).  
Besides small molecule’s methylation, the class I MTases also includes DNA 
5-methylcytosine methyltransferases (Dnmts) (85). DNA methylation is 
essentially involved in a variety of cellular processes, including regulating 
gene expression, mutation repair, genetic imprinting, and maintenance of 
genome integrity, development and diseases etc.(86). The diversity of the 
Class I structure is further demonstrated by existence of a large family of RNA 
5-methylcytosine MTases within this class (87), as well as RNA 6-
methyladenosine MTase, etc. Although the largest group of protein 
methyltransferases (PMTs), which are the SET-domain protein 
methyltransferases, belong to the class V MTases, some of the PMTs belong 
to class I MTases.  All known SET-domain MTases working on  lysine 
residues on various nuclear proteins are involved in chromatin function and 
transcription regulation, including Rubisco and cytochrome C (88). 
1.4.2 A diverse set of structure features for each MTase class 
Almost all MTases catalyse the methyl transfer in an SN2-like mechanism. 
However, distinct mechanisms have been employed  to transfer the methyl-
group to different atom in various substrates. 
Methyl transfer to nitrogen atoms: [D/N/S]PP[Y/F] motif, or DPPY, is a 
common motif for substrate binding in N atom methylation and is present in 
DNA 6’ N adenine and DNA 4’ N cytosine MTases, and protein 5’ N 
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glutamine MTase (89). The diversity of substrates indicates that the DPPY 
motif is not nucleotide specific, but is selective for nitrogen’s conjugation to a 
planar system such as an amide moiety or a nucleotide base(90), (91). DPPY 
motif is absent in some small molecule’s MTase, such as glycine-N MTase 
(GNMT)(92) and phenylethanolamine-N MTase (PNMT)(93) and both of 
them use acidic residue(s) to neutralize the positive charge on the substrate 
amino group (94), so is the case for METTL2, 6 ,8 proteins, since they lack 
the DPPY motif, as shown in  
Methyl transfer to carbon atoms: A significant number of crystal structures are 
solved for DNA C5-cytosine MTases with substrate bound, which transfer the 
methyl group on to carbon (95, 96). A Pro-Cys dipeptide is highly conserved 
within the active site of C5 cytosine MTases, and structurally resembles the 
PY part in DPPY motif. In M.HhaI, the 4’ nitrogen of the cytosine is poised 
far away from SAM, in order to present the C5 atom as a more accessible 
methylation target. Methyl transfer towards C atoms is more difficult than to 
polarizable N atoms,  the cytosine must first be activated by given a negative 
charge by a covalent bond formation, which will help the methyl transfer(97).  
Methyl transfer to oxygen atoms: Several O-MTases’ crystal structures have 
been solved, such as catechol O-MTase (COMT) (98) , the Chalcone O-
methyltransferase (ChOMT) and isoflavone O-methyltransferase (IOMT) (99) 
and the glutamate O-MTase CheR (100). An Mg2+ ion is required to orient the 
substrate-binding site, and a nearby lysine residue appears to deprotonate the 
substrate hydroxyl before targeting the methyl group on SAM. Neither 
ChOMT nor IOMT requires a metal ion, but they do need a histidine residue 
to deprotonate the hydroxyls in plant metabolites. 
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1.4.3 Methyltransferase like (METTL) proteins and their substrates 
There are more than 30 genes assigned as methyltransferase like protein (Mettl) 
genes by the HUGO Gene Nomenclature Committee (HGNC), from Mettl1, 
Mettl2A&B, Mettl3 to Mettl25 etc. mainly due to the reason that they harbor a 
putative methyltransferase domain and have not been well characterized. 
Biochemistry and Biological functions of some of the Mettl proteins were 
revealed, as summarized in Table.  METTL1 is identified as a 7-
methylguanosine methyltransferase responsible for the formation of N(7)-
methylguanine at position 46 (m7G46) in tRNA (101), METTL3 is identified  
as mRNA N6-adenosine Methyltransferase (102), and is recently found to 
form a stable heterodimer core complex with METTL14, which is also found 
to be able to catalyzes m6A mRNA methylation(103). METTL4’s homolog in 
C.elegants is recently found to be the methyltransferase catalyzing m6A 
methylation in genomic DNA and raised the possibility that 6mA may be a 
carrier of heritable epigenetic information in eukaryotes (In press and personal 
Communication, Prof. Shi Yang, Harvard Medical School). Human METTL20 
methylate electron transfer flavoprotein β (ETFβ), thereby inhibiting its ability 
to mediate electron transfer from acyl-CoA dehydrogenases. METTL10 was 
found methylating lysine residues of eukaryotic elongation factor 1A in 
Saccharomyces cerevisiae (104), Mettl11A was found to be a N-terminal Xaa-
Pro-Lys N-methyltransferase (105). As we could see, METTL1 to METTL25 
was found to catalysing Methyl-Group transfer towards a diverse range of 
substrates including DNA, RNA, and Proteins.   However, the majority of 
Mettl proteins in mammalian still remain poorly studied including Mettl2, 6, 8. 
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Table 1-1 Examples for methyltransferase-like proteins 
 Aliases Function 
Mettl1 tRNA (Guanine(46)-
N(7))-Methyltransferase 
Catalyzes the formation of N(7)-
methylguanine at position 46 (m7G46) in 
tRNA 
Mettl3 mRNA M(6)A 
Methyltransferase 
subunit 
This enzyme is involved in the 
posttranscriptional methylation of internal 
adenosine residues in eukaryotic mRNAs, 
forming N6-methyladenosine 
Mettl4 m6A Mtase in DNA N6A Mtase in Worm & Fly’s genomic 
DNA 
Mettl9 DORA Reverse Strand 
Protein 
Probable methyltransferase 




Mettl13 Antiapoptotic Protein 
FEAT 
Probable methyltransferase 
Mettl14 m6A Mtase in mRNA N6-methyladenosine in mRNA 
Mettl17 Protein RSM22 
Homolog, 
Mitochondrial 
May be a component of the mitochondrial 
small ribosomal subunit  
Mettl18 Probable histidine 
methyltransferase  
Probable histidine methyltransferase  
Mettl19 tRNA Methyltransferase Probable tRNA (Uracil-O(2)-)-
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Protein histidine methyltransferase 
 
1.5 3-methylcytidine (m3C) and its corresponding methyltransferase 
3-methylcytosine occurs at position 32 of certain tRNA species 
3-methylcytidine (m3C) is one kind of methylation modification formed by 
adding a methyl group onto the 3’ position in cytosine base attached to either a 
deoxyribose or ribose. 3-methylcytosine in DNA is an alkylation lesion. The 
N1 position on adenosine and N3‐position on cytidine are nucleophilic 
centres most reactive to alkylating chemicals. The highly toxic m1A and both 
mutagenic and toxic m3C are major products in single‐stranded DNA or RNA 
only, since base pairing protects these positions from methylation in dsDNA.  
 
 
Figure 1-3 Chemical structure of cytidine, 3-methylcytidine (m3C), and 
proposed mechanism for m3C formation 
Cytosine is lined to ribose to form cytidine, in which the numbering of 
pyrimidine ring is indicated by numbers, notice the methyl group from S-
adenosyl-methionine (SAM) is transferred to the position 3 nitrogen atom on 
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the pyrimidine ring by nucleophilic attack. The exact enzyme active site 
remain elusive. 
 
3-methylcytidine was first discovered in 1963 from yeast RNA(106) and 
found in both eukaryotic rRNAs and tRNAs (107, 108). As shown in the 
Figure 1-4 , which is obtained from database(109), along with published 
papers, m3C is localized at position 32 of  a number of threonine, serine and 
arginine’s corresponding tRNA species from both cytoplasm and mitochondria 
(110) (111) . Interestingly, m3C is also found at e2 on the long variable loop of 
several cytoplasmic tRNASer species. In Bakers’s yeast, m3C is located at 
position 32 of tRNAThr1 and tRNASer1(110, 112), which is at the junction of 
anticodon stem and anticodon loop, one residue away from anticodon 
(position 34-36). Residue cytidine at position 32, together with its 
modification, such as m3C, is proposed to regulate accurate codon recognition 
at the A-site, proper ribosomal conformation at the P-site, discrimination of 
synonymous codons, etc. Importantly, in the anticodon loop of tRNA, residue 
at 32 usually forms a non-canonical base pair with the residue at 38 (113). It 
has been proposed that the 32-38 base pair is important for tRNA-ribosomal 
interaction, which will be extensively reviewed in 1.7 and 3.19. It is proposed 
that if a methyl group is added on the N atom at position 3, one of the three 
hydrogen bonds between C and G or C and A could be impaired , but the 
biological significance of this change is a mystery. In short, the interactions 
among 32, 38 residues, ribosomal proteins and RNA could be vital towards 
tRNA’s interaction with mRNA and ribosome, and reading frame maintenance 




Figure 1-4 m3C occurs at position 32 of several tRNA species 
The single quotation mark ‘ indicate 3-methylcytosine and were highlighted in 
yellow, figure are drawn from the tRNA database(114) by search against ‘ (3-
methylcytosine) at position 32 
ABP140 is the methyltransferase for 3-methylcytosine in Saccharomyces 
cerevisiae  
In 2011, two groups published in the same issue the journal RNA, in which 
they found ABP140 (Actin-binding Protein 140 kDa) is the MTase responsible 
for installing m3C at position 32 on some tRNASer and tRNAThr species in S. 
cerevisiae (47, 115), and they named it TRM140 (tRNA methyltransferase, 
140 kDa). Both groups identified the enzyme via their in house genetic and 
biochemical screening, one used ribonucleome analysis and the other 
developed a primer extension assay screening. One group a knockdown of 
human Mettl2B and observe significant loss of 3-methylcytidine in HeLa cells 
using Mass spectrometry, further support Mettl2B as a human ortholog to 
Abp140 (115). 
Disruption of the Abp140 gene did not lead to a lethal phenotype, only a 
double KO strain of ABP140 and TRMT1, which is responsible for m2,2 G 
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modification, show a higher sensitivity towards cycloheximide, indicating a 
possible role of ABP140 in translation. Recently, a chemical genetic approach 
showed an ABP140 KO strain showed higher sensitivity to neomycin which is 
aminoglycoside antibiotic target the A-site decoding centre (116). This result 
implies that m3C at position 32 might modulate the A-site decoding when 
neomycin is added. Moreover, it is necessary to test phenotype of ABP140 KO 
under various stresses as mentioned earlier, including nutrient starvation, 
response certain chemicals, especially certain type of alkylation reagents, as 
discussed below in codon biased translation(117), to observe other phenotypes 
related to ABP140. 
1.6 m3C in tRNA has shown to be involved in codon-biased translation  
As stated above, m3C is present at position 32 of tRNA ThrIGU, tRNA SerUGA, 
and tRNA SerCGA in S. cerevisiae, which reads tRNAs reading codons ACT, 
TCA and TCG, respectively(7). Position 32 is adjacent to the anticodon from 
34 to 36 and has the potential to modulate codon- anticodon interactions. It 
was hypothesized that alkylation agents, such as MMS treatment would cause 
hypermodification of those tRNAs, thus leading to changes in translation rate 
and/or fidelity of mRNAs containing high levels of threonine and serine 
codons. One group observed SN2 alkylating agents caused differential 
upregulation of m3C in tRNA, which is mechanically similar to H2O2-induced 
increases in m5C that led to selective translation of mRNAs enriched in  Leu 
codon TTG(118).javascript:void(0); Moreover, the increase in mcm5U 
following MMS exposure has been linked to Trm9 and to the selective 
translation of mRNAs enriched with the Arg codon AGA(119). Following the 
line of logic for m5C and mcm5U, the group demonstrated a coordinated 
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translational stress response system involving stress-specific reprogramming 
of tRNA modifications that leads to selective translation of codon-biased 
mRNAs representing different classes of critical response proteins. tRNA 
modification subpatterns distinguished SN1 from SN2 alkylating agents, with 
SN2-induced increases in m3C in tRNA mechanistically linked to selective 
translation of threonine-rich membrane proteins from genes enriched with 
threonine’s degenerate codons ACC and ACT (117). 
1.7 Phylogeny and potential functions of tRNA 32–38 pair 
Located at the junction of anticodon loop and anticodon stem of tRNAs, 
residue at position 32 of tRNA are most frequently conserved as pyrimidines 
(Y) and usually forms a non-canonical base pair with the residue at 38(120), 
which is most frequently adenosine or uridine(120). Because of its critical 
location near the anticodon which is position 34, 35 and 36, 32-38 base pair 
has been involved in many tRNA functions including several post-
transcriptional modifications(121), intron splicing(122), and aminoacylation 
(123).  A comparison of over 5600 tRNA genomic sequences in E. Coli (114, 
124) reveals an uneven base compositions at position 32–38. C-A, U-A and U-
U are the most frequent and pairs containing G are least common. The 
majority of 32–38 pairs have been assigned to two different families of non-
Watson-Crick base pairs. C32-A38, U32-C38, U32-A38 and C32-C38 pairs as 
well as corresponding pairs containing modified residues are included into 
family I. Cm32–A38 is one example for family I, in which a bifurcated 
hydrogen bond is formed between the 2’ Oxygen atoms of cytidine and the 6’ 
Nitrogen of adenosine. Family II contains the unmodified U32–U38 pair or U-
U pairs containing Ψ. A single hydrogen bond is formed between the 3’ 
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Nitrogen of Uridine 32 and the 4’ Oxygen of Uridine 38. Of note, more than 
90% of all 32–38 pairs belong to one of these two families, with several other 
base pair belongs to family III(125). 
1.7.1 32-38 pairs in several tRNAs ensure uniform binding to the 
ribosomal A site and reading frame maintenance at P sites   
A series of studies showed that the 32-38 pair on tRNA2Ala adjust tRNA 
affinity to the ribosome A site (126). When several different anticodons were 
cloned into tRNAAla2, all mutated tRNAs interact with their corresponding 
codons at A site much weaker than WT tRNAAla2 (126). Further experiments 
revealed that tighter ribosomal binding was restored with WT tRNA sequence. 
In short, different 32-38 pairs will have different effects on changing the 
binding affinity of tRNA with the ribosome. It is hypothesized that tRNAAla2 
has evolved to have 32-38 pairs that weaken its ribosomal binding to have 
similar binding affinity with other tRNAs. Interestingly, tRNA2Pro in E. Coli 
which has a stable 5’-GGG-3’ with 5’-CCC-3’ pair, also harbours either a 
32A-38U or the 32C-38G pair to decrease the affinity on tRNA binding. It 
also was observed that when either the modifications on tRNA or the esterified 
amino acid were removed, the binding of different tRNA towards A and P 
sites on ribosome were no longer uniform while nature occurring tRNAs 
showed similar affinity(127, 128), supporting the above hypothesis. More 
studies on ribosomal A sites’ affinity to tRNA reveals that tRNAGly of E. Coli 
binds tighter to both cognate and near-cognate GUC codon at the A-site of the 
ribosome when U to C mutation occurs at position 32 (129), while mutations 
at position 32 and 38 caused misincorporation of Ala at the near cognate GUC 
codon (113). Thus, the 32–38 pair has been used by multiple tRNAs to adjust 
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the affinity towards ribosome, and it is likely other tRNAs will adapt a similar 
strategy. 
At the P-site of the ribosome, ribosomal protein S9 contacts residues 32, 33 
and 34 on peptidyl-tRNAs(130, 131), which resulted in an increase in +1 
frameshifting, indicating that the contact between S9 and residue 32 has a 
critical role in reading frame maintenance(132). Moreover, after the finding 
that tRNA suppressor efficiency is primarily defined by the ASL(133, 134),  it 
has been shown that 32-38 pair modulate the functions of UAG, UAA and 
UGA tRNA suppressors (134).   
1.7.2 The 32-38 pair and discrimination of synonymous codons  
Another study on pair 32-38 was showed in several in vitro translation assays 
using glycine tRNAs (129, 135, 136). For reading four glycine codons, GGA, 
GGT, GGC, GGG, E. coli use three tRNAGly isoacceptors, whereas 
Mycoplasma mycoides only has tRNAGly(UCC). The only different nucleotide 
between tRNAGlyUCC of  E. coli and M. mycoides in the anticodon loop is 
position 32. It was shown that discrimination of the 3rd codon position was at 
least partially dependent on residue at position 32 since a U32 to C32 mutation 
lose the discrimination on glycine codons. Thus, it is position 32 that is able to 
fine tune the ability to recognize four glycine codons.  
For mechanistic studies on the observation above, it was worthwhile to test E. 
Coli tRNA1Gly U32C mutant’s binding to cognate codons and third position 
mismatches in the ribosomal A site, since previous studies demonstrated that 
32-38 pair has a role in tRNA affinity to the ribosome (126). While wild type 
tRNA1Gly could form stable complexes with the near-cognate GGC, GGA and 
GGU glycine codons, the dissociation rate was too fast to measure and 
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indicates an over 50 fold faster dissociation from these mismatched codons 
than from the cognate GGG codon. In contrast, the mutated tRNA1Gly (U32C) 
dissociated from the three mismatched codons much more slower with a rate 
only about 12-fold faster than dissociating from its cognate GGG codon (128). 
An equilibrium binding assay also confirms the trends observed with the Koff 
assay, further confirms that tRNA1GlyU32C has a higher affinity to near-
cognate codons than wild type tRNA1Gly. Therefore, the mutation in some way 
stabilized tRNA binding to ribosome and the nucleotides in WT tRNA 
weakens the binding(136). 
It was suggested that 32-38 pair could adjust translational process by inducing 
conformation changes upon interaction with ribosomal residues(137, 138). 
However, the solved crystal structure of the A site shows no direct contacts 
between 32 or 38 nucleotides with ribosome(139) and biochemical 
experiments showed that only several 16S rRNA nucleotides has interaction 
with A site tRNA (140), all of which are located far from 32–38 pair (136, 
141). It is possible that the 32–38 pair could indirectly modulate tRNA’s 
affinity to the ribosome by modulating the anticodon loop conformation (120, 
142).  
1.7.3 Extended anticodon hypothesis 
The above evidence clearly suggest the importance of the 32-38 pair of 
aminoacyl-tRNAs in uniform and accurate codon recognition at both A-site 
and P-site. An extended anticodon hypothesis is proposed based on the 
evidence that tRNA anticodons correlated with nucleotides in the Anticodon 
Stem Loop (ASL) It is proposed residues 37 and 38, as well as several pairs in 
the anticodon loop-stem such as 32-38 pair, have evolved to suit the three 
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nucleotides in anticodon(143). In other words, each tRNA species may have 
evolved to match its anticodon to compensate for the different properties 
among aa-tRNAs , so that each aa-tRNA could be used relatively equivalently 
by the translational machinery(144).  
One limitation of the above experiments is that binding or dissociation rates 
obtained from in vitro assay are far slower to those under normal translation. It 
is estimated that they are approximately 103–104 slower than the rates of  
tRNAs’ entrance and leave to the A site in cells. Nevertheless, X-ray solved 
structures support the above conclusion (120). On the other hand, it was 
shown that the accuracy of tRNA recognition in vivo mainly depends on the 
GTP hydrolysis kinetics and peptide bond formation, not on how tight tRNA 
bind to ribosome or how fast the disassociation rates (145). It is therefore 
needed to analyse the 32–38 pair in fine tuning translation using assays that 
can measure the tRNA kinetics in different steps in translation, such as 
ribosome profiling (146).  
1.8 The study of translational control of gene expression by ribosome 
profiling 
As discussed above, the potential functions of 3-methylcytosine at position 32 
in certain tRNAs in translation fine tuning calls for assay to observe the subtle 
effects. Here, a recent development of ribosome profiling by next generation 
sequencing is discussed for planned study of m3C. 
1.8.1 mRNA abundance is far from a good proxy towards gene 
expression 
Measurements of messenger RNA (mRNA) abundance at global level using 
microarray or second generation sequencing have already greatly advanced the 
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study of regulation of gene expression(147) . However, there is a demanding 
need for direct identification and monitor proteins synthesized in cells for 
several reasons. First, mRNA levels cannot reflect real protein production 
since transcribed mRNA is subject to extensive post-transcriptional, 
translational and post-translational regulation (148-150) . Second, the effects 
from upstream ORFs (uORFs), internal ribosome entry sites (IRES), non-
AUG start codons, and nonsense mediated read-through make it impossible to 
predict the exact protein product from the transcript sequence at the moment 
(151, 152). Third, ribosomal pausing during translation is revealed to help the 
co-translational folding and secretion of some proteins, thus prevent accurate 
predicting of protein production by mRNA abundance (153-155). In General, 
the correlation between mRNA abundance and protein remains poor 
frequently, thus levels of mRNA is far from a perfect proxy the gene 
expression.  
1.8.2 Limitations of quantitative proteomics and polysome profiling 
followed by Microarray 
Advances in unbiased quantitative proteomics such as SILAC provides 
information about the identity and abundance of proteins at a time point (148, 
149). However, there are still considerable limits on their ability to monitor 
protein translation on individual mRNA, regarding initiation, elongation or 
termination, as well as determine protein sequences independently or  measure 
low-abundance proteins, thus cannot currently match the depth or the breadth 
of coverage that is obtainable from nucleic acid deep sequencing. 
Polysome profiling followed by microarray, in which mRNAs are recovered 
from fractions of mRNA with different number of loaded ribosomes and sent 
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for microarray or RNA-seq, could provide a estimate of protein synthesis(156). 
However, this approach is hindered by the low resolution of fractions that 
have more than a few ribosomes per transcript, as well as that analyses of 
RNA from those fractions cannot indicates the position of ribosome on the 
transcript(157).  
1.8.3 Global ribosome profiling as a promising tool to reveal functions 
of ‘minor’/’unimportant’ modifications 
Ribosome profiling (Riso-seq) is a method based on deep sequencing of 
ribosome-protected mRNA fragments. Purification and sequencing of these 
fragments provides a snapshot of all the ribosomes which are actively engaged 
in translation at a specific time point(158). This information can determine 
what proteins are being actively translated in a population of cells, providing 
information for investigating translational control; determining the rate of 
protein synthesis; studying frameshifting; predicting protein abundance, 
etc(157). The origins of the approach can be traced back to the finding that 
endoribonucleases treatment could convert polyribosome to monomeric 
ribosomes that is each bound to a short protected mRNA fragment. These 
assay named nuclease footprinting was first exploited to map the translation 
initiation sites of prokaryotic bacteriophage RNA(159) and eukaryotic 
reovirus RNAs(160). Because of the disability of adapting Sanger sequencing 
to genome-wide in that era, these experiments have to adopt cell-free 
translation systems tailed preferably with a single mRNA species (160). It was 
the advent of deep sequencing technologies, and the associated methods of 
cDNA libraries constructions that opened up the possibility of using the 
method to globally map the positions of ribosomes on mRNAs in intact cells.  
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One of the most important innovations of the method was to generate the 
protected mRNA fragments using E. coli RNase I, which has little sequence 
specificity, in contrast to the nucleases used previously (RNase A, RNase T1, 
or micrococcal nuclease). Such is the precision of RNase I cutting especially 
at the 5′-end, that the positions of ribosomes along the ORF can be determined 
with single nucleotide precision, and the footprints show a clear trinucleotide 
periodicity, which allows assignment of the translation reading frame and 
distinguishes footprints arising from translating ribosomes from RNA 
fragments that are protected for any other reasons. Ribosome profiling has 
been applied in mainly three aspects of translation study: the mechanism of 
protein synthesis, the identification of translated mRNA of the transcriptome, 
and translational control of gene expression (157, 161). The first of which is 





2 CHAPTER 2. MATERIALS AND METHODS 
2.1 Plasmids constructions 
For recombinant DNA cloning and plasmid amplification, E.coli strain DH5α / 
TOP10 (Invitrogen) was used as host. Bacteria cells were grown in LB liquid 
or on solid medium with ampicillin (100μg/ml) for selection of positive clones. 
Mouse Mettl2 was cloned from C57BL/6 E13 embryo liver cDNA pool and 
cloned into pPyCAGIP vector (gift from Dr. Wu Qiang, NUS) by XhoI/NotI. 
Human Mettl2 was cloned from human cervical cancer cell line HeLa S3 and 
inserted into pPyCAGIP vector by XhoI/NotI with Flag tag at N-terminus and 
HA tag at C-terminus. Point mutations at three Glycine residues and deletion 
mutation at SANT, SAM, motif were carried out following PCR based 
mutagenesis method (Quikchange). For bacterial expression, human Mettl2 
WT and ΔSAM cDNA were subcloned into pGEX6P1 vector by XhoI/EcoRI. 
pPyCAGIP-Flag-Mettl2-HA was further modified into pPyCAGIP-Flag-
Mettl8-HA-T2A-EGFP by insertion of T2A peptide 
gagggcagaggaagtcttctaacatgcggtgacgtggagg- agaatcctggccca and EGFP cDNA, 
which is cleaved in cells. All plasmids are verified by sequencing. pLKO.1 
vectors harboring shRNA against Mettl2, Mettl8 and scramble control were 
either cloned or purchased from RNAi consortium through Sigma. A list of 
plasmids generated or purchased, and oligos used in generating plasmids are 
listed in the appendix. 
2.2 Cell culture and treatment 
All used cell lines, such as HEK293T, HeLa S3, A172, HCT116 (p53 wild 
type and isogeneic p53-/-), U2OS and HepG2 were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal-bovine 
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serum (FBS) (Sigma, Gibco, thermoscientific) and antibiotics (100 units/ml 
penicillin and 100 μg/ml streptomycin) otherwise specified. H1229 cells were 
cultured in RPMI-1640 medium with the same supplements as above. The 
cells were incubated at 37 °C with a humidified atmosphere of 5% CO2.  UV 
radiation is performed in Stratagene Stratalinker UV Crosslinker 2400. 
Gamma irradiation is performed in BioBeam 8000 irradiator (Gamma Service 
Medical GmbH, Leipzig, Germany) with 137Cs as radiation source (dosage at 
0.048Gy/sec).  
2.3 Transfection 
2.3.1 Cationic liposomes based Transfection  
Lipofectamine 2000, Lipo RNAiMax or Mirus TransIT were used according 
to Manufacturer’s instructions;  
2.3.2 Calcium phosphate precipitation based transfection  
Calcium phosphate precipitation was done only in 293T/293 cells when 
confluency reaches 40%-60%. 20 μg of plasmid DNA in 450μl autoclaved 
sterile Milli-Q water was mixed with 50μl of 2.5M freshly-made calcium 
chloride. Then 500μl of 2×BES buffer (50 mM BES, 15 mM Na2HPO4, 280 
mM NaCl. Adjust pH to 6.95 with 1 N NaOH) was added and the whole 
solution was vortexed immediately for 1 min followed by a 20 min incubation 
at room temperature to allow DNA precipitation. After incubation, the DNA 
solution was briefly spin down, pipetted up and down several times, and added 
evenly to dishes in a drop-wise manner. The transfected cells were incubated 
at 37 °C with 2.5% CO2. After about 16h, media was removed and replaced 
with 10ml fresh media. Then cells were moved back to 37 °C incubator with 5% 
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CO2 until cells reached full confluency for further passages, lysate/RNA 
collection or virus harvest. 
2.3.3 Lenti-Virus mediated transduction  
Modified from Broad Institute, RNAi Consortium: To produce lentiviruses 
producing shRNA, shRNA-pLKO.1 plasmid or pLKO.1 control plasmid was 
transiently transfected into 293T packaging cells with 3rd generation lenti 
virus packaging plasmid and Envelop plasmid (VSVG & Gal-Pol) for 
producing viral particles by calcium phosphate precipitation. For the viral 
transduction in cells, Sigma protocol was followed. Briefly, cells to be 
transduced were seeded at appropriate density on Day 0. The next day 
lentiviruses were added to cells in growth media containing polybrene (6-8 
μg/ml). Media was removed and replaced with fresh growth media on Day 2. 
After one or two days (cell type dependent) to wait for cells to robustly 
express puromycin resistant gene, media was removed and replaced with 
containing puromycin medium. After certain days of puromycin selection 
(concentration and cell type dependent), medium containing dead cells was 
removed and the remaining cell population was supposed to express shRNA of 
interest. The sequences of the shRNAs used are in Table 2-8. All the shRNA 
oligos were cloned or purchased from Sigma or IDT. 
2.4 Real-time PCR 
Total RNA was harvested using Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions, purified by the RNeasy mini kit (Qiagen), and 
then reverse transcribed using the M-MLV Reverse Transcriptase system 
(Promega) or Superscript III (Invitrogen). The cDNA products were subjected 
to RT–PCR with KAPA SYBR® FAST Universal 2X qPCR Master Mix 
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(KK4600) using a 7300 or 7500 Real-Time PCR machine (Applied 
Biosystems). All mRNA expression values were normalized against the 
internal housekeeping gene GAPDH 
2.5 Western Blot 
Appropriate amount of lysate samples were electrophoresed on a 
polyacrylamide gel of a percentage dependent on the size of the target protein, 
transferred onto a PVDF membrane in cold room and probed with primary 
antibodies of interest at 4 °C overnight. The following experiment was 
processed using HRP conjugated secondary antibody (Biorad ) and enhanced 
chemiluminescence visualization method (various bands, e.g. Thermo 
Scientific). 
2.5.1 Making resolving gel and stacking gel 
Table 2-1 Resolving gel recipe 
Resolving Gel* 
(15 ml ) 
8 % 10%  12%  15%  
Water (ml) 7.0 5.9 5.0 3.5 
30 % Acrylamide mixv(ml) 4.0 5.0 6.0 7.5 
1.5 M Tris, pH 8.8 (ml) 3.8 3.8 3.8 3.8 
10 % SDS (µl) 150 150 150 150 
10 % Ammonium Persulfate (µl) 150 150 150 150 
TEMED (µl) 36 24 24 24 




Table 2-2 Stacking gel recipe 
Stacking Gel (4ml) 4%  
Water (ml) 2.7 
30 % Acrylamide mixv(ml) 0.67 
1.5 M Tris, pH 8.8 (ml) 0.5 
10 % SDS (µl) 40 
10 % Ammonium Persulfate (µl) 40 
TEMED (µl) 16 
Total (ml) 4 
 
Use ethanol to clean the glasses and green rack; Load resolving gel up to the 
green bottom line; Load 1mL of isopropanol at the top of the resolving gel; 
Wait for around 30 min; Remove water by inverting and placing the filter 
papers; Load stacking gel up to the top of the glass plate; Insert comb; Wait 
for 30-45 min; Remove comb by pulling it straight up slowly; 
2.5.2 Sample preparation 
Centrifuge samples at 13000 rpm for 2 min; Remove supernatant; Spin again 
at 13000 rpm for a few seconds; Use a smaller pipette to remove supernatant; 
Use 100μL of 50 mM Tris-HCl, 300 mM NaCl, including Protease inhibiors, 
and 0.1 Triton to Resuspend and lyse cells, boiled on 100℃ hot plate; Add 
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30μL of loading dye to the two sets of tubes containing supernatant and 
pallet  ; Denature at 100℃ for 8-10 min ;  
2.5.3 Sample loading and gel running 
Table 2-3 10X Running Buffer 
Tris 30g 
Glycine 144g 
MilliQ water Up to 1L 
 
Table 2-4 1X Running Buffer 
10X running buffer 100 mL 
20% SDS 5 mL 
MilliQ water 900 mL 
 
Insert the gel block into the tank, comb face inward; Add gel dam if only one 
gel is used; Fully fill the compartment between 2 gels with tank buffer; Load 
30-35μL of sample into wells (40uL maximum) Amt of protein: 20ug; Load 
6μL pre-stained marker in the first well; Half fill both side of the tank with 
tank buffer; Close the lid and connect the circuit  ; Run gel at 100V~200 V, 
time depends ;  
 
2.5.4 Transfer  






Prepare a container with 
methanol ; Use a forceps to remove the cover of the membrane and emerge it 
into methanol ; Prepare a container with transfer buffer ; Emerge the filter 
papers into the transfer buffer(4 filter papers per gel) ; Prepare transfer set-up 
accordingly. Avoid bubbles between gel and membrane; 




Filter Paper X2 
Gel 
Membrane 




Close cassette firmly and place it in module.(black face black) ; Place frozen 
ice pack into the tank( on the black side) ; Fill tank with 1X transfer buffer ; 
Run at 100V for 1.5-2hr until the marker bands reaches expected positions;  
10X running buffer 100mL 
Methanol 200mL 




Dispense 10mL of 5% milk (blocking solution) into a container; Place the 
membrane in the blocking solution; Place on the shaker for 1hr, room temp or 
overnight at 4℃;  
2.5.6 Primary antibody & secondary antibody 
Rinse membrane with 1XTBST 2 times (Optional) ; Wash membrane with 
1XTBST for 15min, 2/3 times (Optional) ; Incubate membrane with Primary 
Antibody  overnight at 4℃ ; Antibody can be re-used for one more time ;  
Rinse membrane with 1XTBST 2 times ; Wash membrane with 1XTBST for 
15min, 3 times ; Incubate membrane with 2o antibody for 1hr at RT, or 
overnight at 4℃ ; Discard the Secondary Antibody ;  
2.5.7 Film development 
Rinse membrane with 1XTBST 2 times ; Wash membrane with 1XTBST for 
15min, 2 times ; Wash membrane with 1XTBS for 15min ; Prepare a cling 
wrap ; Drain membrane and place it on the wrap ; Add 1mL of 
chemiluminescent HRP substrate to each membrane(ECL) ; (1:1-500mL white 
bottle +500mL black bottle) 975uL Big, 25uL Small bottle ; Wait 1 min for 
development and drain the extra HRP(ECL) ; Wrap the membrane, avoid 
bubbles ; Bring film, membrane, cassette, scissors, timer to dark room ; Cut 
film to appropriate size, cut the corner as a marker ; Place membrane and film 
into cassette for 30s ; Place film in the machine ; Adjust time accordingly ;  
2.6 CRISPR/Cas9 gene targeting in both human and mice 
Vector pST1374-NLS-flag-linker-Cas9 containing human-codon-optimized 
Cas9 and human-gRNA-expression vector MLM3636 were from Addgene. 
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MLM3636 vectors with gRNAs targeting human Mettl2A, Mettl2B or both 
locus were self-made following instructions of Joung Lab. Cells were 
transiently transfected with Cas9 plasmid and gRNA expression vectors using 
lipofectamine/Mirus following manufacture’s protocols. Cells were 
transfected in 24-well plates using 0.5 μg of the Cas9 expression plasmid and 
0.3 μg of the RNA expression plasmid. Two days after transfection, cells were 
trypsinized and replated in 10 cm dishes with a highly diluted passage ratio for 
single clone selection. After about two weeks, single clones were picked and 
cultured in individual wells. The selection of positive clones was done first by 
western blot analysis of Mettl8 expression. Then genomic DNA of the Mettl8-
null clones was extracted by phenol-chloroform method, and then subjected to 
PCR, TA cloning and sequencing to confirm the mutation of the target genes. 
With the help from Model Animal Research Center of Nanjing University, our 
group successfully got METTL2, 6 and 8 constitutive KO mice. The mice are 
shipped to Singapore and maintained. Three pairs of sgRNA for D10A CAS9 
has been assembled to the U6-promoter driven expression vector. The sgRNA 
efficiency has been verified. The sgRNA3 and sgRNA3 D10A has been 
transcribed and injected to the Mettl8+/- fertilized egg. Tails of the founder 
mice (45 founders). PCR has been performed to validate the mutation status of 
the loci. qPCR was performed to check mRNA of Mettl2, 6, or 8. 
 
2.7 Modifed quantitative PCR to measure m3C modification (qPCR-m3C) 
A quantitative PCR (qPCR) based method was modified to measure m3C 
modification (162). Each Serine or Threonine tRNA was reverse-transcribed 
in two reactions using two primers, in which reverse primer r1 was able to 
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anneal to the middle of this tRNA, overlap with the nucleotide at Cytosine 32, 
and reverse primer r2 was designed to target the region 3’ to Cytosine 32. 
Subsequent qPCR was performed and generated two Ct Value Ct r1 and Ct r2, 
corresponding to data generated by reverse primer r1 and r2, respectively. The 
difference between Ct r1and Ctr2 (hereafter dCtr2r1) was calculated by 
subtracting Ct r1 from Ct r2. The ∆Ct-r2r1value was compared between RNA 
from WT or KD/KO cells  
For isolation of total RNA from cells, Trizol reagents (Life Technologies) was 
used according to the manufacturer's protocol. Particular tRNA species, such 
as tRNA Thr (AGU), was further purified with biotin labelled oligos linked to 
Strepavidin Dyna beads, as described previously. The tRNASer & tRNA Thr 
isolated from wild-type (WT) and Mettl2A/2B KD/KO cells were subjected to 
qPCR-m3C  Threshold cycle (Ct) values calculated with the manufacturer's 
software (Life Technologies, 7300 System SDS Software) are indicated in this 
figure.  For absolute quantification of m3C modification in crude total RNA, 
we subjected total RNA isolated from WT and Mettl2A/2B KD/KO cells to 
qPCR-m3C.  Reverse Transcription and qPCR: The total amount of RNA 
isolated from cells and tissues was adjusted to 100 ng/μL in RNase-free water, 
unless otherwise indicated. To avoid genomic contamination, we digested 2 
μL (200 ng) total RNA with 5 U DNase I (Ambion) in a 20-μL reaction at 
37 °C for 20 min. We then heat-inactivated the DNase I at 75 °C for 10 min. 
After the DNase treatment, we mixed 2.5 μL digested total RNA with 1 μL 20 
μmol/L reverse primer r1 or reverse primer r2, heat-denatured the mixture at 
65 °C for 10 min, and cooled it rapidly on ice for at least 5 min. With the 
mixture still on ice, recombinant reverse transcriptase (M-MLV RT/ AMV RT 
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Promega) was added to a final concentration of 0.5 U/μL. Reverse 
transcription was performed in a total reaction volume of 10 μL at 55 °C for 
30 min and then heat-inactivated at 85 °C for 5 min. We subjected 2 μL 
synthesized cDNA to qPCR with the SYBR Master Mix kit (KAPA) and the 
ABI PRISM 7300 Real-Time PCR System (Life Technologies) according to 
the manufacturers' instructions 
 
2.8 Primer extension analysis of modifications in RNA 
Table 2 listed the oligos used in primer extension assay. To label oligos, 10-30 
pmol primers were labeled with 2 times pmol  (20-60pmol) γ-32P ATP 
(Perkin Elmer’s BLU002Z500UC ) using T4 polynucleotide kinase (NEB), 
followed by removal of excess label using G25 chromatography column (GE 
healthcare). Primer extension assays were done as described in. In a 10 µL 
reaction, 1-2 pmol of 5′ end-labeled primers were annealed to 2 µg total RNA 
(for testing cytoplasmic tRNA) or 10 µg total RNA (for testing mitochondria 
tRNA ) in 0.5 µL  Superscript III buffer and by heating to 70°C for 5 min and 
slowing cooling (turning off heat block/water bath )done to 37 °C for 20-30 
min. The annealed reaction was then extended using 1 µL Superscript III 
(Invitrogen) and 0.11 mM of each dNTP (A, C, G, and T) for 30min at 50 °C -
55°C. The reaction was stopped by adding 1 × RNA load dye (formamide 
containing 0.1% bromophenol blue), heated for 5 min to 95 °C, cooled on ice, 
and loaded onto 15% polyacrylamide gel (20cm long. The longest gel in the 
institute) containing 6-8 M urea. The gel was dried on vacuum dryer (Bio-Rad) 
and exposed in a cassette with Phosphor Screen using different exposure time. 
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Table 2-7 5' end labelling of DNA probes for primer extension 
Components  Amount  
Primer 30 pmol  
10X T4PNK Reaction 
Buffer 
4 µl 
 [γ-32P] ATP  
6000Ci/mmol 
50 pmol  
T4PNK 2 µl (20 units) 
Water up to 40 µl 
 
Reverse Transcription 











GAACCCAGGATCTCCTGTTTAC 22 25 
m3C-G35-
Thr(UGU) 
GAACTCGCGACCCCTGGTTTAC 22 24 
m3C-G35-
Thr(UGU2) 
GAACTCGCGACCCCTGGTTTAC 22 25 
m3C-U39-
Ser(AGA) 













GATCCATTGACCTCTGGGTTAC 22 24 
3C-mito-
Ser(GCT) 
TAGACATGGGGGCATGAGTTAG 22 24 
m3C-mito-
Ser(TGA) 
TCGAACCCCCCAAAGCTGGTTTC 23 25 
 
2.9 Recombinant protein purification for MTase assay and growing 
crystals  
Either His-Tagged or GST-tagged Proteins was usually purified by affinity 
column first and by size exclusion column using FPLC.  
2.9.1 Cell harvest  
For large scale expression, usually 5 litres E. coli were grown and harvested.. 
Inoculate a single colony of BL21 E. Coli carrying desired plasmid into 20 ml 
LB medium (100 µg/ml Amp) and culture overnight at 37 ℃. Dilute amount 
of overnight culture into 1 L LB medium to obtain an OD600 at less than 0.1 
and culture at 37 ℃ for 3-4 hour when OD600 reaches approx. 0.5-0.8. Add 
IPTG to 0.1-0.5 mM and culture 12-16 hours at 15 ℃. Pellet cells at in a 
polystyrene plastic bags in JA-10 rotors’ bottles at 6,000 rpm for 20 mins and 
use liquid nitrogen to freeze the pellets to store at -80 ℃ or proceeded to 
affinity purification.  
2.9.2 Disruption of cells by French press and column loading 
Resuspend cell pellets in 50 - 100 ml lysis buffer (20 mM NaH2PO4, 300 mM 
NaCl, 10 mM imidazole, add 0.1 % (v/v) Triton X-100 and β-mecarpoethnal 
to 5mM just before resuspension. Incubate on ice for 20 mins with stirring and 
homogenize the cells using a homogenizer, otherwise it would clog the French 
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press system; Use French press to break the cell (PANDA system); Or use 
sonication 10 sec pulses with 10 sec intervals (30% amplitude) on ice until 
suspension becomes partially clarified, (around 30 mins), centrifuge at 15,000 
rpm in JA-20 for 20 mins ; Load supernatant into column and collect the flow-
through; For PANDA system: Open the machine half an hour before use, to 
cool down to 7 degree; Wash with milliQ water and later with the buffer you 
used to lysate the cells, add the cell supernatant and then adjust the pressure to 
600-700 mPa; wait for three minutes between each run;  
2.9.3 Wash and elution 
Wash column with wash buffer (20 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH 8.0); Elute protein in an increasing concentration of imidazole 
in elution buffer (20 mM NaH2PO4, 300 mM NaCl, and 500 mM imidazole, 
pH 8.0). Analyse selected fractions by SDS-PAGE, collect desired fractions 
and dialyse or concentrate against buffer suitable for size exclusion 
chromatography. Perform gel filtration in a similar manner using Hiload, 
Superdex 16/60cm, one GEL filtration buffer receipt for METTL2, 6, 8 
purification: 20mM Tris-HCl, 500mM NaCl,  pH 7.5. 
2.10 In Vitro Transcription (IVT) of tRNA  
tRNA was In vitro transcribed to serve as potential substrates for METTL2. 
T7 RNA Polymerase catalyses the synthesis of RNA in the 5’- 3’ direction in 
the presence of a DNA template containing a T7 phage promoter. In this study, 
tRNA is In Vitro Transcribed to serve as substrates for 3-methylcytosine In 
Vitro reconstitution. PCR products containing T7 RNA Polymerase promoter 
in the correct orientation can be transcribed. Due to the complexity of multiple 
copies and secondary structure of tRNA gene, gBlocks® Gene 
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Fragments(IDT), which are double-stranded, sequence-verified genomic 
blocks are ordered (200ng) and further amplified by PCR and served as 
templates for IVT. PCR mixture is purified in a silica based PCR clean-up 
column (Qiagen/Thermo) to ensure better yields in the IVT reactions. PCR 
products is examined on agarose gels to estimate concentration and to confirm 
amplicon size prior to its use as a template in the IVT.  Template size is 
important in optimizing optimal template input. The optimum template 
concentration ranges could be up to several micromolar for transcripts around 
75nt, since shorter transcripts needs higher template concentrations. 1-2 μg of 
PCR fragments are used in a 50 μl in vitro transcription reaction.  Reaction is 
assembled at room temperature in the following order in Table. Mix 
thoroughly, pulse-spin and incubate at 37°C for 2-4 hours. To remove 
template DNA, add 2 μl of DNase I (Ambion, RNase-free), mix and incubate 
at 37°C for 15 minutes. To remove potential RNase, add Protease K to 200 
μg/ml with 0.5 % SDS. Transcribed tRNA was finally purified by 
Phenol/chloroform extraction and alcohol precipitation. 
2.11 Purification of specific tRNA species by solid-phase DNA probes  
Modified from(163): Oligodeoxyribonucleotides (about 30 nt) with sequences 
complementary to the 3’ side of target tRNAs were synthesized with 
biotinlyted 5’ end, immobilized on streptavidin C1 dynabeads (Invitrogen) and 
used as solid-phase probes. A mixture of tRNAs was added to a suspension of 
the solid-phase probe in 2.4 M tetraethylammonium chloride and incubated for 
10-30 min. Only a target tRNA hybridized with the immobilized probe at 
appropriate temperatures and was eluted out by heating.  The sequences of the 
52 
 
3’-biotinylated DNA probes complementary to human tRNAThr AGU and 
tRNASer UGA were: respectively. 
2.12 Reconstitution of 3-methylcytosine by recombinant Mettl2B 
The reaction mixture (100 μL) contained 1 times T7 RNA polymerase buffer, 
200 ng of small RNAs (<200nt, by Mireasy kits), and 10-20 µg recombinant 
Mettl2B, in the presence or absence of 0.5-1 mM Ado-Met. The reactions 
were incubated for 0.5 h at 30°C, 0.5 h at 37 °C. After incubation, the 
reactions was precipitated by 1.5 volume of 100% Ethanol and go through 
RNA microcolumns, eluted and assayed by Primer extension assay as 
mentioned above. 
Table 2-9 In Vitro Transcription Reactions 
Reagent μl 
10X Reaction Buffer 5 
ATP (100mM) 5 
UTP (100mM) 5 
CTP (100mM) 5 
GTP (100mM) 5 
Nuclease-free water Xul 
Template DNA from PCR 10ug 
T7 RNA Polymerase Mix 2ul 
Total reaction volume 50.0 
 




Nuclease-free water  
10X RNA MTase Buffer  
  
tRNA  
Recombinant Protein  
SAM (32 mM)  
Total reaction volume 50.0 
 
2.13 Methyltransferase assay using tritium labelled S-
adenosylmethionine ( 3H-SAM ) 
2.13.1 In vitro 3H-SAM binding assay  
10µg recombinant GST, GST-Mettl2 WT and ΔSAM protein were conjugated 
to 10 µl Glutathione Sepharose 4B at 4 for 30min before being incubated with 
5μl 3H-SAM (12-18 Ci/mmol (444-666 GBq/mmol)) at 30°C for 30min. After 
two washes with 0.5ml 100mM Tris-HCl at pH 7.5, the beads were transferred 
to scintillation tube and mixed with 2 ml scintillant cocktail (OptiPhase HiSafe 
2, Perkin Elmer). The result was obtained from triplicate reactions on Wallac 
1414 Liquid Scintillation counter controlled by the WinSpectral software 
system. 
2.13.2 In vitro Methyltransferase assay using scintillation counter or 
fluorography 
In vitro Methyltransferase assay was either measured by a scintillation counter 
or by fluorography. For scintillation based assay, tRNA from either WT or 
METTL2, 6, 8 Knockdown or knockout cells were incubated with 2.5 μl 3H-
SAM and 10 µg recombinant proteins and went through G25 spin based size 
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exclusion columns to get rid of unincorporated 3H-SAM. Scintillation 
counting was compared between WT and KD/KO samples. For fluorography 
based methods, In vitro reactions were purified by G25 spin columns to get rid 
of unincorporated 3H-SAM and directly loaded on the 15% Urea SDS-PAGE, 
enhanced using 3H-Enhancer and precipitated using cold water and PEG8000, 
dried and exposed to X-ray film at -80 °C. Double stranded DNA ladders were 
labelled by M.Sssl and 3H-SAM 
2.14 Mass spectrometry in this project 
In this project, several experiments relays on the Mass spectrometry to obtain 
information, such as identification of automethylation sites on METTL2, 6, 8 
proteins (performed at Zhao Yingmin’s lab at Shanghai); resolving protein 
complex pulled down by Flag IP following manufactors’ protocols   ; PAR-
CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and 
Immunoprecipitation) followed by identification of crosslinked RNA species, 
performed by Prof. He Chuan’s lab at Univeristy of Chicago; and 
quantification of 3-methylcytosine, which is described below 
2.15 Size exclusion HPLC and LC-MS/MS for quantification of 
modified ribonucleosides  
Total RNA quality and composition was determined using Bioanalyzer Nano 
6000 Chips. tRNA were isolated from samples with RIN > 8 were using size 
exclusion HPLC as previously described by(164). Briefly, total RNA was 
separated into its components using a Bio SEC-3 column (Agilent; ID: 4.6 mm, 
length: 300 mm, particle size: 3 µm, pore size: 100 Å) under isocratic elution 
of 100 mM ammonium acetate at flow rates of 1 mL/min at 60 ○C. tRNA 
fractions were collected, concentrated with a 10 KDa MWCO spin filter, spin-
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dialyzed against ultra-pure water and quantified by Ribogreen fluorescence 
(Invitrogen). 2 µg of tRNA from each sample were enzymatically hydrolyzed 
to nucleosides using benzonase (Sigma), nuclease P1 (Sigma) and bacterial 
alkaline phosphotase (Invitrogen) in the presence of antioxidants and 
deaminase inhibitors, cleaned up by spin-dialysis, resolved by HPLC using a 
Hypersil Gold aQ column (Thermo Scientific, ID: 3 mm, length: 50 mm, 
particle size: 1.9 µm) using a gradient elusion between ultrapure water with 
0.1% (v/v) formic acid and acetonitrile (LC-MS grade, Merck) with 0.1% (v/v) 
formic acid at 25 ○C, and analyzed on a Agilent 6460 triple quadrupole mass 
spectrometer by multiple-reaction monitoring (MRM) in positive ion mode. 
Transitions for adenosine (A) 268.1  136.1 m/z, guanosine (G) 284.1  
152.1 m/z, uridine (U) 245.1  113.1 m/z, cytidine (C) 244.1  112.1 m/z, 
m3C, m5C and 4-methylcytidine (m4C), 258.1  126.1 m/z, were used for 
relative quantification. Instrumentation for this process is described (165).  
 
2.16 RNA immunoprecipitation (RIP) assay 
RIP assay were performed to validate METTL2, 8 binding targets identified 
by PAR-CLIP. RIP is analogous to IP, with different purpose. RIP immno-
precipitates a s RNA binding protein (RBP) and associated different RNA 
species that can be detected by RT-PCR, real-time PCR, microarrays or RNA-
seq. Below is the RIP protocol adapted from (166, 167)   
2.16.1 Collecting cytoplasmic and nuclear cell lysis and RIP 
Prepare fresh cell lysis buffer as in section 2.5.2 (plus adding RNase 
inhibitor) , Add lysis buffer to collected cell pellets keep on ice for 20 min 
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with frequent mixing. Centrifugation at 10,000 g for 10 min to pellet nucleus. 
It is of critical importance to avoid contamination by RNase or DNase.  
2.16.2 RNA Immunoprecipitation 
Add antibody (1 to 8 µg) to supernatant (5 mg-10 mg) and incubate for 
overnight at 4ºC with rotation. Add protein A/G beads (40 µl) and incubate for 
1 hr at 4ºC with gentle rotation. Washing conditions need to be optimized. 
Pellet beads at 2,500 rpm for 30 sec or using magnetic rack if using dyna 
beads , remove supernatant, and resuspend beads in 500 µl RIP buffer. Repeat 
for a total of three RIP washes, followed by one wash in PBS. Purification of 
RNA by resuspending beads in TRIzol or other similar RNA extraction 
reagent. Elute RNA with nuclease-free water (e.g. 20 μl). Add approximately 
15-25 μl (depending on yield) of either DEPC treated water or Nuclease free 
water to the RNA pellet.  
2.16.3 Reverse transcription (RT)-PCR   
Perform reverse transcription of DNase treated RNA according to 
manufacturer’s instructions. If candidate target is obtained by PAR-CLIP or 
other assay, PCR or qPCR could be directly used towards suspected targets; if 
target is not known, cDNA libraries could be analysed by microarrays or 2nd 
generation sequencing. The control experiments should give no detectable 
products after PCR amplification. 
2.17 Polysome profiling- 
2.17.1 Preparation of 10% and 50% W/V sucrose:  
Weigh 5g (10%) or 25g (50%) of sucrose into a 50ml Falcon tube; Add RNase 
free water to sucrose at 35 ml mark; Add the following:  
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Table 2-11 Sucrose stock solution 
Components Stock Volume 
75mM KCl 2M KCl 1.875ml 
1.5mM MgCl 1M MgCl 75 µl 
10mM Tris-HCl pH7.4 1M Tris-Hcl pH 7.4 500 µl 
Place in boiling distilled water for 15 mins. Shake gently to mix sucrose every 
minute or so; Cool on ice; Add water to a final volume of 50ML; Filter 
through a 0.45um filter into a fresh 50ML falcon tube. Store at -20 ℃ until use. 
 
2.17.2 Preparation of buffers 
Table 2-12 2X Resuspension Buffer (RSB) Recipe 
Components Stock Volume 
20mM Tris-Hcl (pH7.4) 1M 200 µl 
300mM NaCl                               5M 600 µl 
30mM MgCl                                1M 300 µl 
ddWater  8.9 ml 
Final Volume                                             10 ml 
 
Table 2-13 1x RSB with Cycloheximide  
(Resuspension Buffer, for 2 samples) 
Components Stock Volume 
2 x RSB  2 x  150 µl 
SuperasIn  20 U/µl 22.5 µl 
200 µg/ml Cycloheximide 100mg/ml  0.6 µl  
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Rnase free ddH2O    126.9 µl 
Total     300 µl 
Make fresh each day 
Table 2-14 1X Lysis Buffer  
(For 2 samples, make fresh each day) 
Components Stock Volume 
2 x RSB                                 2 x  500 µl 
1% Triton X                                    10% stock 100 µl 
2% Tween 10% stock 200 µl 
1% deoxycholate 10% stock 100 µl 
RNase free ddH2O  100 µl 
Total  1000 µl 
 
2.17.3 Cell harvest and sucrose gradient profiling  
Cells are treated for 10 minutes with 100ug/ML Cyclohexamide at 37 ℃ 
incubator; Wash the cells with warm PBS (with 100ug/ML cycloheximide 
1:1000); Cells are harvest by trypsinization (with 100ug/ml cycloheximide 
1:1000) and neutralized with ice cold media with FBS (with 100ug/ml 
cycloheximide 1:1000) ; Spin the cells at 1500rpm for 5 mins 4℃. Add 1 ml 
of the cold PBS (with 100ug/ML cycloheximide 1:1000) Transfer into a new 
1.5ml cold tube. Take out 50ul AND ADD 1ml TRIZOL. This is the total 
RNA; Spin and wash the cells with cold PBS for 2 mins, 2000rpm twice For 
SW41 gradient samples use the larger volumes.  For SW60 gradient samples 
use the smaller volumes in brackets.  Resuspend cell pellet in 300 (150) µl 
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Fresh RSB. Take out 320 (160) µl and put into a fresh cold 1.5ml tube. Add in 
the same volume of 320 (160) µl Fresh Lysis Buffer. Mix gently and leave it 
on ice for 10 mins. Shake gently every 2 minutes. Spin full speed for 3 mins to 
remove nuclei. Nuclear pellet will be smaller and whiter than the cell pellet. 
Transfer about 600 (300) µl extract into a new cold tube and spin full speed 
for 10 mins. Transfer into another new tube. Take out 10ul extract to measure 
the OD units (1/50 dilution). Take 50ul extract as unfractionated lysate. Add 
1ml Trizol. SW41 only - Add 400ul of 10% sucrose to the top of the sucrose 
gradient (10%-50%) and weigh the tubes.  Measure and load the same OD 
Units onto sucrose gradient. Total vol: 400 (250) ul. Top up with 2xRSB if 
necessary.  
 
Making Sucrose gradients: Gradients should be made while the cells are being 
washed. Each spin cycle is 5 mins during which time gradient is prepared.  
Chill the centrifuge buckets on ice for 30 mins before spin. Insert kimiwipes 
into tube to collect condensation. Clean tubes, caps and syringe with RNase-
away (Ambion) and wash with nuclease free water and leave to dry (Do this 
early in the morning); Add the room temp 10% filtered sucrose to the first 
mark ; Add the room temp 50% filtered sucrose to the second mark. Put in the 
long caps gently to avoid bubbles.  
Use the biocomp gradient machine. Level the machine and choose the 
program. SW41-List- long caps 10%-50% w/v; After gradient formation, 
remove cap gently. Do not tilt the tube or disrupt the gradient.  
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Add 400ul 10% sucrose (200ul twice by p200) on top of gradient very gently 
to avoid mixing of sucrose with lower layers – No lid present. Weigh the tubes 
and adjust weight with 10% sucrose. Do not disturb the gradient. Add in the 
sample extract and if necessary, top up with 2xRSB; Label the side of each 
tube with sample name and note which bucket is used. Place gradients in the 
chilled buckets and load 400ul of sample. Seal bucket tightly with the lid.(0-
rings must be recently greased); Spin at 8 ℃, 36000rpm, 1.5hrs - 2hrs in 
beckman centrifuge  
 
Collecting the fractions (after the 1.5-2hrs ultracentrifuge spin)   Prepare and 
label RNAse free 2ML eppendorfs on ice. Collect 1ml in each fractions. After 
fractionations, add in 110ul of 10% SDS and 12ul of proteinase k (20mg/ml). 
Incubate and shake at 42 ℃, 30 mins.  Samples are stored at -80 ℃. 
 
2.18 Immunoprecipitation 
Cell lysate was extracted in lysis buffer (50 mM Tris-HCl pH 7.5, 0.1 mM 
EGTA, 1% Triton X-100, 5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 0.27 M sucrose, 0.1% (v/v) 2-ME, 
plus 1 tablet/50 ml of EDTA free complete protease inhibitor cocktail 
(Roche)). Protein lysates from cells were centrifuged at 14,000 × g for 5 min 
at 4 °C and the insoluble debris discarded. Protein concentrations were 
determined using Bio-Rad protein assay dye. 10 μl of Flag M2 beads (for Flag 
IP) (Sigma) or 2 μg of relevant antibody coupled to 10 μl of protein G-agarose 
beads (Thermo Scientific) were washed with 1ml lysis buffer before 
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incubation with 1mg total lysate for 1 h at 4 °C on a 1000rpm orbital shaker. 
Proteins bound to the beads were separated from the cell lysis by 10,000 g 
centrifugation for 1 min, washed twice with 1 ml of lysis buffer with 0.5 M 
NaCl and twice with 1 ml buffer B (50 mM Tris-HCl, 0.27 M sucrose and 0.1% 
(v/v) 2-ME, pH 7.5). After removing all the remaining supernatant, SDS-
Laemmli buffer was added to the beads to denature the antibody and release 
the immunoprecipitated protein. The samples were boiled for 10 min before 
being subjected to SDS- PAGE electrophoresis and subsequent Western 
blotting analysis.  
2.19 Immunofluorescence staining for cultured cell lines (IF-IC) 
Cells grown on glass cover slips were washed with PBS solution, fixed in 4% 
paraformaldehyde at room temperature for 10-15 min and permeabilized with 
PBS (0.2% Triton X-100) for 10 min, then blocked with 3% BSA in PBS (0.1% 
Triton X-100) for 1 hour at room temperature, followed by incubation with 
primary antibodies at 4 °C overnight. Cells were washed three times with 0.1% 
Triton X-100 in PBS, 10 min each time and incubated with fluorescence-
labelled secondary antibodies in dark at room temperature for 1h. Nuclei 
counterstaining were performed using 0.005% DAPI staining. Coverslips with 
cells were mounted onto slides by VECTASHIELD Hard-set Mounting 
Medium (Vector Laboratories, H-1400). Microscopy Image acquisition and 
analysis was performed using Nikon A1R-A1 confocal microscopy system, 
which is owed by Cancer Science Institute, Singapore. 
2.20 Codon-run reporter constructs 
pEF6 vector is inserted with codon optimized Renilla luciferase (Rluc) and 
Firefly luciferase (luc2) cloned from pMirGlo from Promega using oligos 
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below, with stop codon for Rluc excluded. Renilla luciferase was inserted into 
pEF6’s via KpnI and BamHI RE sites located at Multiple cloning sites while 
firefly luciferase was inserted using EcoRI and NotI, thus leaving 5’-ACT 
AGT CCA GTG TGG TG-3’ linker located between Renilla luciferase and 
Firefly luciferase. 






Runs of codons matching the anticodons of several human tRNAs which is 
approved or suspected to have m3C were generated by annealing DNA oligos 
containing BamHI/EcoRI overhangs at either ends and harboring five or ten 
successive, identical Threonine, Serine, or Glycine codons or Control codons, 
and inserted between the BamHI and EcoRI sites downstream of the Rluc2 
and upstream of luc2. The Fluc/Rluc ratio on transfection of the constructs 
into cells from METTL2 KO or WT cells was determined using luciferase 
assay. Luciferases was done using passive lysis buffer according to 
manufacturer’s instruction (Promega Dual Luciferase kit) and measured 
manually in triplicate.  
Table 2-16 Oligos for Codon Runs 
























2.21 Scripts for calculating codon numbers for mRNA  
import gzip 
#gzip is the txt file for ref_seq mRNA 
N = ['A','C','G','T'] 
codons = [] 
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for a in N: 
 for b in N: 
  for c in N: 
   codons.append(a+b+c) 
def doCount(seq): 
    thisCount = [0 for i in range(len(codons))] 
    if len(seq) % 3 != 0: 
        print "Not divisible by 3"; return thisCount 
    for i in range(0, len(seq), 3): 
        thisCount[ codons.index(seq[i:i+3]) ] += 1 
    return thisCount 
 
ccdsToid = (113) 
convert = False 
 
f = gzip.open("refseq.UCSC.hg19.fa.gz", 'rb') 
out = open("hg19.refseq.count.txt", 'w') 
 
currSeq = None 




out.write("\t".join(codons) + "\n") 
for r in f: 
    if r[0] == '>': 
        if currSeq != None: 
            currCount = doCount( currSeq ); 
            if not convert: #or currName.split(' ')[0].split('_')[-1] in ccdsToid: 
                out.write(currName + '\t') 
                #out.write( ccdsToid[currName.split(' ')[0].split('_')[-1]] + '\t') 
                out.write('\t'.join(map(str,currCount)) + '\n') 
            else: 
          print "no conversion" 
        currName = '_'.join(r.strip().split(' ')[0].split('_')[2:]) 
        currSeq = None 
    else: 
        if currSeq == None: 
            currSeq = r.strip() 
        else: 




2.22 Clonogenic assay  
Clonogenic assay of cells in vitro were adapted from(168). Cell counting and 
uniform seeding is of critical importance in this assay. Colonies at the bottom 
of the vessels were fixed in 3 - 4% paraformaldehyde (v/v) and stained using 
crystal violet 0.5% (wt /v) dissolved in water. 
Treatment could be performed either before or after cells are plated into dishes. 
The first option is often used for a quick screening of the sensitivity of cells to 
different treatments. In the second option, cells are treated in dishes and 
subsequently re-plated in appropriate dilutions to assess clonogenic ability. 
The re-plating may be performed immediately after treatment (IP) or it may be 
delayed (DP) to allow recovery. It is often used in radiobiology to study lethal- 
or sub-lethal damage repair. 
Stop cell growth when control dishes have obtained sufficiently large and 
round colonies. Wash gently with PBS and fix by covering plates with 3%-4% 
paraformaldehyde for 10 to 15 minutes, remove and rinse with PBS, add 
crystal violet solutions and stain for around 20 min and submerge the plates 
into tap water. Leave the vessels to dry at room temperature.  
SeaPlaqueTM Agarose with low melting temperature (Lonza, 50100) was used 
in Colony Formation. In a triplicate manner, 1.5ml culture medium with 0.6% 
agarose was first plated into each well of a 6-well plate. After base agarose 
solidified, another 1.5ml of 0.4% agarose was plated on top in culture medium 
containing 2500 cells per well. After 20 days colonies grown in soft agar were 
stained by 1 mg/ml Thiazolyl Blue Tetrazolium Bromide (Sigma, M5655) 
dissolve in water and then scanned in Bio-Rad Gel Doc EZ system. A 
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population with more than 50 cells was counted as one surviving colony. 




3 CHAPTER 3. RESULTS  
3.1 Sequence alignment of METTL2 with its paralogs and homologs  
Mammalian homologs of ABP140 were searched against BLAST and found 
Methyltransferase-like protein 2A & 2B (Mettl2A, 2B) and Methyltransferase-
like protein 2 (Mettl2) as human and mouse orthologues, respectively, with 
Mettl8 and Mettl6 ranking at second and third position in the BLAST list. As 
shown in Figure 3-1 (A), METTL2A, 2B, METTL6 and METTL8 are sharing 
high sequence homology and thus are considered as paralogs with each other. 
METTL2, 6, 8 possess the conserved SAM and nucleotide binding motif in 
TRM140, but lack the N-terminal region of TRM140. METTL6 is shorter than 
METTL2A, 2B, and 8 for lacking of another approximately 80 amino acids at 
N-terminal, the so-called SANT domain (169, 170). Searching for Mettl2A, 
2B’s homologs in mammalians and sequence alignment by Clustal W 
indicates they are really conserved as shown Figure 3-1(B), and homologs are 
identified in zebra fish as METTL2A, 2B, 6, 8; C. elegans as Y53F4B.42, and 
even in Trypanosoma Brucei.as XP_827431 (GenBank: EAN77101.1). These 
phylogenic studies showed TRM140 are quite conserved through evolution, 
and even creates three or four highly similar paralogs as Metttl2, 6, 8 or 
Mettl2A, 2B, 6, 8 in mammalians, implying a potential indispensable role of 











Figure 3-1 Sequence alignment of the METTL2 with its paralogs and 
homologs 
(A) Clustal W sequence alignment of the human METTL2A, 2B, METTL6 
and METTL8 proteins; with putative domain/motifs shown in red dashed 
boxes; Accession numbers are NP_859076.3 (METTL2A), NP_060866.2 
(METTL2B), NP_689609.2 (METTL6) and NP_079046.2 (METTL8) 
(B) Sequence alignment of full length mouse METTL2,6,8 proteins 
(C) Sequence alignment showing the conservation of Mettl2, 6, 8 from baker’s 
yeast to higher mammalians, Accession numbers are as follows: Drosophila 
melanogaster: NP 647636.3; Schizosaccharomyces pombe: CAB76043.1; 
Saccharomyces cerevisiae YOR239W; Pan troglodytes: XP 001144324.1; 
Gallus gallus: NP 001006329.1; Canis lupus: XP 537604.3; Bos Taurus: NP 
001068714.1; Rattus norvegicus: NP 001102309.1; Caenorhabditis elegans: 
NP 001040827.1; Danio rerio: NP 001017902.1; Trypanosoma brucei:XP 
827431.1 
(D) Alignment of all human threonine tRNA isodecoders. Sequences are 
obtained from GtRNAdb database (171) 
 
3.2 Subcellular localizations of METTL2, 6 and 8 
The study of localizations of METTL2, 6, 8 will provide insights into the 
subcellular localizations of the methyl transfer reactions. The antibody which 
successfully distinguished lysates in Western Blot between METTL2 WT and 
KO by Cas9/CRISPR were chosen for immunofluorescence staining. As 
shown in Figure 3-2 (A) and (B), METTL2 was found to be both in the 
nucleolus (as co-localized with the nucleolus marker: Fibrillarin) with a strong 
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signal and cytoplasm with a relatively weaker signals in and HeLaS3 cells. For 
another Glioma cell line A172, METTL2 is found in both nucleolus as well as 
cytoplasm, though signal intensity is close in both compartments. Consistently, 
the localization of METTL2 in the nucleolus was found in Snu387, HEK293T, 
HepG2, H1229, U251MG, HCT116, primary human fibroblasts, etc. 
(Confocal images available upon request). It is noteworthy to mention 
METTL2 signals are lost in the nucleolus in cells during Mitotic phase, 
indicating a possible cell cycle dependent localizations of METTL2. 
Intriguingly, Ectopic overexpressed Flag-tagged, EGFP-tagged or YFP-tagged 
METTL2 was only found to be in the cytoplasm, perhaps due to disturbed 
nucleolus localization signals by tagging Flag, EGFP, or YFP. Intriguingly, 
both the nucleolus and cytoplasm localization signals of METTL2 was still 
maintained in T2-1 #3 & #7 METTL2 KO cell clones, indicating either the 
antibody recognize the smallest isoform of METTL2, which is not deleted in 




Figure 3-2 Subcellular localizations of METTL2, 6, 8 
(A), (B) Endogenous METTL2 localizations in HeLa S3 cell line; cells during 
mitosis are cycled in (B). 
(C) Endogenous METTL2 localizations in A172 human brain glioblastoma 
cell line. 
(D) Ectopic overexpressed METTL2-YFP fusion proteins in HeLa S3 cell line. 




Interestingly, METTL8 was found to be localized in the nucleus too, which 
indicates a possible interplay with ATM signalling pathway in the nucleus. 
Both endogenous and ectopic expressed METTL6 was found only in 
cytoplasm, supporting its interaction with Serine-tRNA synthase (SARS), 
though human seryl-tRNA synthetase was found to be in the nucleus to 
perform its non-canonical functions towards VEGFA (172, 173).  
 
3.3 Generation of Mettl2A&2B double KO in  HEK293T cell line 
tRNA and rRNA have relatively longer half-life compared with other RNA 
species as stated in introduction. Moreover, shRNA or siRNA based 
knockdown usually cannot totally abolished mRNA targets. To ensure 
complete abolishment of potential modifications on tRNAs, we established 
CRISPR/Cas9 mediated knockout cell lines following the instruction of ZiFit 
to design targeting guiding RNA (gRNA) on both human Mettl2A and 
Mettl2B coding regions.  
Three colonies using one gRNA with different deletion mutations which could 
cause pre-mature stop of translation were obtained and mutations were 
confirmed by TA cloning and Sanger sequencing as shown in Figure 3.3 (B) 
and western blot confirmed the knockout the METT2A, 2B full-length protein 
at 43KDa Figure 3.3C using two multiclonal METTL2A&2B antibodies 
purchased from Abmart, designated as Abmart 1 and Abmart2, although extra 
bands were shown in WB on the right panel by using in house purified 
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METTL2 antibody, probably due to non-specific binding. Real time PCR 
revealed over 20 fold reduction of METTL2 
Off-target effect of the gRNA was evaluated according to bioinformatics tool 
developed by Zhang Feng group. There was no mutation on the top off-target 
candidates by sequencing. Nevertheless, whole genome sequencing or using 
double nickase Cas9 are needed to fully confirm no off-target effects in those 
clones. Those KO cells serves a better source of RNA than Knockdown cells 
as revealed by primer extension assay in Figure 3-6 and Figure 3-7, are being 










Figure 3-3 CRISPR/Cas9 mediated Mettl2A & 2B gene knockout in 293T 
cells 
(A) Diagram of guide RNA targets on both human Mettl2A&2B mRNA and 
the sequence of gRNA1, which successfully generate three different M2 KO 
clones, is listed below.  
(B) Genomic DNA Sequencing results of individual wildtype or knockout 
clones were aligned to the respective target region of gRNA1 used. Mutations 
or Deletions of various lengths were indicated in blue compared with human 
Mettl2A and Mettl2B ref_seq sequence.  
(C) Equal amount of lysates from different Mettl2 knockout clones and 
controls were resolved on SDS PAGE gel and probed with Hsp90 and three 
human Mettl2A&2B antibodies, designated as a-Mettl2 abmart1, a-Mettl2 
abmart2, a-Mettl2 in house purified. (notice of some potential non-specific 
bands using in house purified Mettl2 antibody) 
(D) Relative Quantitative Real time PCR analysis of WT HEK293T and a 






3.4 Recombinant METTL2 protein is prone to aggregate under normal 
purification conditions 
To obtain sufficient amount of purified recombinant proteins for in vitro 
MTase assay and crystals growing for METTL2, 6, 8, large scale prokaryotic 
expressions and purifications of METTL2, 6, 8 proteins, together with certain 
mutants were performed. In all Class I MTase sequences, as reviewed in 1.4.1, 
GxGxG motif is a signature for co-factor SAM binding. For generation of 
methyl-transfer inactive METTL2B mutants, its GCGVG sequence, together 
with another extra 3 amino acid residues at 5 Prime and 1 amino acid residue 
at 3 Prime(169, 170), were deleted (27 nt deletion in total) and designated as 
M2-∆SAM. For a more mild disruption of the protein structure, a GCGVGN 
to ACAVAN (designated M2-G3A, three Glycine to Alanine) mutants were 
obtained. METTL6 and METTL8 ∆SAM and G3A mutants were generated in 
a similar manner. Taken together, METTL2B and its abovementioned mutants, 
were subcloned in to either pGEX series or PET15b/21a series of prokaryotic 
expression vectors. Small scale tests were performed to obtain the optimal 
concentration of IPTG induction and temperature for E. Coli growth and test 
the efficiency of GST tag cleavage by Precision Protease (GE Healthcare). For 
most of the cases, 16 °C and 100 µM IPTG were able to induce protein 
expression quite well and GST tag were efficiently cut by the protease.  
Figure 3.4 (A), right panels. Both GST-tagged and His-tagged METTL2 were 
expressed well in E. Coli BL21 strain in large scale, as sufficient amount of 
proteins were obtained after Nickle affinity columns Figure 3.4(A). However, 
there would be a substantial amount of proteins eluted within the void volume 
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of the column as proteins went through size exclusion columns such as 
Superdex, Figure 3.4 B, indicating protein aggregations or precipitations.  
METTL2, 8 has been predicted to contain a large portion of disordered region 
at N- terminal by XtalPred (174, 175), which may partially explain the 
occurrence of protein aggregations, and indicates it is hard to get  crystals of 
diffraction quality. Indeed, a panel of crystal growth conditions (400 ) towards 
different truncated proteins were tested and failed to obtain high quality 
crystals for X-ray diffractions. (Screen conditions and photos of some crystals 
are available upon request) 
Besides the 43.5 kDa bands in the coomassie blue gels in later fractions in gel 
filtration step, which correspond to full length METTL2, there are higher 
molecular weight proteins which are eluted within the void volume of the 
column, indicating protein aggregates as discussed above. Curiously, those 
METTL2 protein aggregates could not be broken by reducing conditions with 
beta-mercaptoethanol (β-ME) in sample buffer with heating. The proteins 
migrates as approximately 66 kDa proteins in SDS-PAGE, indicating a dimer 
is formed through certain covalent bonds other than disulfide bond, which 
could be broken upon heating in reducing environment. Interestingly, this 
observation is also observed in ABP140, the yeast homologue of METTL2. In 
fact, the molecular weight of ABP140 was around 71.5 kDa based on amino 
acid sequence, but it is actually detected at around 140 kDa by SDS-PAGE 
and that’s where the name ABP140 came from. Likewise, the recombinant 
ABP140 was detected at about 150 kDa due to the 19-kDa C-terminal tag 
(115). The property of METTL2 or ABP140 to form dimers may give hints to 












Figure 3-4 Purification of METTL2 by Affinity and Size Exclusion 
Chromatography 
(A) Schematic diagram for the FPLC purification of Mettl2 protein from E. 
Coli . 
(B) Small scale test for the IPTG induction and Precision protease® cutting 
efficiency of GST-METTL2 fusion protein (right two panels). 
(C) Large scale purification of GST tagged mouse METTL2, GST affinity 
purification at the upper panel and size exclusion purification at the bottom 
panel. 
(D) Large scale purification of human His tagged METTL2B, Nickle affinity 
purification at the upper panel and size exclusion purification at the bottom 
panel. 
 
3.5 tRNAThr AGU and tRNAThr UGU isoacceptors are substrates of 
METTL2 
Generally, all modifications on the Watson-Crick face of the nucleobase 
(including m1A, m3C, m3U, m2,2G, m1G, etc.) are prone to block the 
incorporation of a complementary nucleotide during reverse transcription by 
retrovirus derived reverse transcriptase, while small modifications at the 
Hoogsteen edge often allow unimpeded read-through (44). This difference in 
enzymatic behavior is exploited in the detection of modifications such as m3C 
(47, 115). To validate if human METTL2 could be responsible for m3C in 
certain tRNAs, primer extension assay were performed following published 
work (47, 115). In theory, if 3-methylcytosine is conserved in human during 
evolution, primer extension on threonine or serine tRNA species that contain 
m3C at position 32 will terminate at residue 33, while tRNAs lacking m
3C will 
terminate at another downstream residue which could block reverse 
transcription, which is most likely m2, 2G (N2, N2-dimethylguanosine)as 
from the yeast study(115). Schematic diagram of human tRNAs and 




Figure 3-5 Schematic diagram of human tRNAs and corresponding probes 
used in primer extension assay. 
All probes were labelled at 5’ Prime by γ-32P-ATP and T4 PNK, the four point 
stars indicate cytosine residue at position 32 in tRNAs. 
(A) Schematic of four human cytoplasmic Threonine tRNA Isoacceptors: 
AGU, UGU, UGU2, CGU, (Known modifications not shown, U is shown as 
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T), and probes used for primer extension assay for detecting potential m3C at 
position 32 (m3C32), designated as tThr
AGU, tThrUGU, tThrCGU. They are used 
by reverse transcriptase to anneal to tRNA residues 3’ 56 – 35 5’;  
(B) & (C) Schematic of cytoplasmic tRNA Serine Isoacceptors: AGA, 
CGA,UGA, GCU; Notice the redesign of probes in (C) to avoid long variable 
Arm in threonine tRNAs, since the probes in B showed a “stuttering” pattern 
in primer extension assay 
(D) Mitochondria tRNAs Threonine UGU, Serine GCU and Serine UGA and 
probes. tRNA diagrams in green are adapted from tRNA database (114). 
 
Of note, eukaryotes present not only more tRNA gene content than the other 
two kingdoms but also a higher variation in gene copy number among 
different isoacceptors and isodecoders (176). For example, there are ten 
ThrAGU decoder genes and six ThrUGU genes in human hg19 reference genome 
(171). Luckily, the high sequence similarity among tRNA isoacceptors (Figure 
3-1C) made it possible to design only one or two 32P labelled probes for 
primer extension assay. If m3C is conserved in human tRNAs during evolution, 
primer extension on threonine or serine tRNA species that contain m3C at 
position 32 will terminate at residue 33, while tRNAs lacking m3C will 
terminate at another downstream residue which could block reverse 
transcription, which is most likely m2,2G (N2, N2-dimethylguanosine) as 
inferred from the previous study (115). Indeed, primer extension for total 
RNA from wild type HEK293T cells generates a 24 nt size 32P-ATP labelled 
band which is two nucleotides longer than the free probes, indicating a reverse 
transcription stopping event occurs at position 32 of both tRNA ThrAGU and 
tRNA ThrUGU (Figure 3-6A lane 1, lane 5 and lane 9). In contrast, primer 
extension using RNA from Mettl2A and 2B double KO cells generates a 
higher molecular weight bands, indicating loss of METTL2 would abolish the 
modification at position 32 (Figure 3-6A lane 2, 6, 10), which is 3-
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methycytosine, as supported by the recent ARM-seq (177) and DM tRNA seq 
(176).  
 
Figure 3-6 Loss of METTL2A & 2B abolished the modification at position 32 
in tRNAThrAGU and tRNAThr UGU isoacceptors 
(A). Autoradiography for various primer extension reactions resolved on 15% 
Urea PAGE. RNA used from different cells were indicated under lane number, 
for example, M2 KO under lane 2 indicated RNA used were extracted from 
METTL2 Knockout cells. Notice in lane 2 and 10, two higher size bands were 
pointed out as asterisks on the right which used RNA from METTL2 KO cells.  
Marker lane (M) contains ssDNA probes which is 56 nt and 72 nt in length, 
lane 1-4 used tThrAGU probes, lane 5 -12 used tThrUGU, lane 5-8 used 1/4 dose 
of γ-32P-ATP as compared to lane 1-4 and lane 9-12 ( * donates longer bands 
generated by using RNA from M2 KO cells). 
(B) Longer exposure for (A), notice the same bands pattern in lane 9-12 in (A) 
appears in lane 5 - 8, in which less γ-32P-ATP is used in labelling probes. 
 
3.6 Other substrates for METTL2, 6, 8 remain elusive 
To check if METTL2, 6 and 8 could have other tRNA species as substrates, 
more probes were designed and labelled, including tRNA ThrCGU, (no 
functional tRNA ThrGGU isoacceptors in human) (114), and serine, arginine 
tRNA isoacceptors in both cytoplasm and mitochondria (). Primer extension 
targeting tRNA ThrCGU showed a stuttering pattern, indicates either a low 
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abundance of ThrCGU or poor specificity of  the probes targeting ThrCGU 
(Figure 3-7). Other probes also failed to give a pattern as clear-cut as tRNA 
ThrAGU and ThrUGU probes, despite of trying various conditions of reactions, 
including different dNTP concentration, reaction time and incubation 
temperature, etc. Importantly, there is no clear difference between WT and KO, 
leaving other potential substrates of METTL2, 6, 8 elusive. It is not too 
surprising since reverse transcription profiles of modified RNAs are often 
prone to some kind of stuttering (doubling of the band on the gel) at the 
modified residue that blocks the reverse transcription (44). 
 
 
Figure 3-7 Reduction or loss of METTL2, 6 or 8 has no effects on the position 
32 modification in other tRNA species tested 
(A) Primer extension assay using other tRNA probes, lane 1-4 used SerAGA 
probe, lane 5-8 used SerUGA probe, lane 9 -12 used ThrAGU probe and KO 
clone #7 as repeat to the previous results. Marker lane contains ssDNA probes 
which are 46 nt and 72 nt in length. 
(B) A longer exposure for film of (A), notice some larger size of fragments 




3.7 Ectopic expression of METTL2 in KO cells restore the modification 
which could block primer extension 
Ectopic expression METTL2 Protein were performed to test if ectopic 
METTL2 could restore the modification in vivo. Indeed, the longer cDNA 
were generated in reactions which used RNA from METTL2 overexpressing 
cells. The longer cDNA were generated by both tRNAThr AGU and tRNAThr 
UGU probes, but not tRNAThr CGU, which showed a stuttering pattern, as 
shown in ( 
Figure 3-8). LC-MS/MS analysis was also performed to check m3C level. 
Indeed, m3C is upregulated in cells overexpressing METTL2 (Figure 3-13C). 
 
 
Figure 3-8 Ectopic expression METTL2 protein in KO cells restore the 
position 32 modification in tRNA ThrAGU and ThrUGU 
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(A) Primer extension assay for RNA isolated from Mettl2 KO cells (lane 1 to 
3), or KO cells overexpressing Mettl2 mammalian expression vectors (lane 4 
to 6). Lane 7 to lane 12 are reactions using mitochondria tRNA probes. The 
symbol * indicates larger size bands generated by using RNA from M2 KO 
cells). Marker lane contains ssDNA probes which is 56 nt and 72 nt in length.  
(B) One repeat for (A), in which cells overexpress ectopic METTL2 for 12 
days are assayed for primer extension.  
 
3.8 Recombinant METTL2 could restore the modification on tRNA 
ThrAGU and ThrUGU  
To test if Recombinant METTL2 could methylate tRNAThr AGU and tRNAThr 
UGU in vitro, Methyltransferase were carried out using FPLC purified WT 
METTL2 or two mutants M2-∆SAM and M2-G3A, whose Methyltransferase 
activity are supposed to be lost, as described in 2.1. Indeed, as shown in 
(Figure 3-9 A), higher MW bands were gone in which WT METTL2 proteins 
were added, while G3A mutants failed to restore the modification as seen in 




Figure 3-9 In Vitro reconstitution of modification on tRNA ThrAGU and  
ThrUGU by recombinant METTL2 
(A) In Vitro methyltransferase assay. Protein + in lane 3,4,7,8 indicates N 
terminal 6×His tagged human Mettl2B protein purified from E. coli were 
added. 
(B) G3A mutated human METTL2B proteins are added in lane 2 and lane 6 
reactions and incubated with RNA from KO cells and SAM, in contrast with 
lane 1 and lane 5, in which WT huMettl2B proteins were added. #6 indicates 
another cell clone, which failed to show the abolishment of modification at 
position 32. 
 
3.9 in vitro transcribed tRNAs are not methylated by recombinant 
METTL2 
Unmodified tRNAs were in vitro transcribed using T7 RNA polymerase and 
were served as a potential substrate for METTL2. No m3C32 formation was 
observed in this transcript as shown in (Figure 3-10 ), again, tested by primer 
extension. Some modifications in tRNAs might act as positive determinant for 
m3C formation at position 32. This result suggested that tertiary structure of 
native mature tRNAs, instead of unmodified tRNAs, are required for efficient 
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m3C32 formation in tRNAThr AGU and tRNAThr UGU and both in vitro 
transcribed tRNAs are not good substrates for METTL2 protein.  (unlabelled 
lanes on the right side of the films are control lanes from previous reactions as 
a marker) 
 
Figure 3-10 METTL2B fail to restore position 32 modification on in vitro 
transcribed tRNA ThrAGU and ThrUGU.  
Primer extension using in vitro transcribed tRNA ThrAGU and ThrUGU, as 
described section 2.10. Notice lane 3, 6 are repeats previous results 
 
3.10 A quantitative PCR based assay for m3C quantification  
Due to the tedious and low throughput nature of primer extension assay, a 
quantitative PCR (qPCR) based assay were developed for Measurement of 3-
methylcytosine modification in tRNAThr AGU and tRNAThr UGU (qPCR-m3C), 
inspired and modified from measuring 2-methylthio modification(162). 
tRNAThr AGU, tRNAThr UGU and some other tRNAs, such as tRNASerUGA 
was reverse transcribed with 2 unique primers, with reverse primer r1 
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designed to target a region which includes the Cytosine at 32, and reverse 
primer r2 was designed to anneal to the region downstream of C32. 
Subsequent qPCR was performed to detect the corresponding cDNAs and 
determined the Ct Value for both r1 and r2, the gap between Ct r1 and Ct r2 
(designated ∆Ct r2-r1) showed a difference between RNA from WT and RNA 
from METTL2 knockdown, or METTL2, 6, 8 triple Knockdown, as show in 
Figure 3-11B. Notably, the ∆Ct value is not increased in Triple Knockdown, 
indicating METTL6 plays a minor role in threonine tRNA modification 
(Figure 3-11D). However, a similar design to tRNAserUGA failed to get 
reasonable Ct r1 and Ct r2, since the Ct r1 is supposed to be smaller than Ct r2, 
as shown in (C). These results may reflect a similar situation to stuttering 
pattern in traditional primer extension assay, probably due to the long variable 
arm in cytoplasm serine tRNAs. qPCR-m3C were actually developed before 
the primer extension assay in the above figures, and it offered a potential faster 
and semi-quantitative way for assessing 3-methylcytosine modification levels 
in certain tRNAs. Further titrations needed to be performed if a quantitative 







Figure 3-11 Quantitative PCR based assay for quantification of m3C (qPCR-
m3C) 
(A) Cartoon showing the work flow of the assay 
(B) Schematic diagram of human tRNAs and corresponding probes used in 
primer Extension 
(C) and (D) m3C Real time PCR results for tRNAThrAGU and SerUGA , 
respectively 
 
3.11 LC-MS/MS analysis of m3C contents in various RNA species 
To support the above finding by primer extension assay and study the 
contribution of m3C by METTL2 family proteins, quantitative analysis of 
ribonucleotide modifications is performed by size exclusion HPLC and triple 
quadrupole mass spectrometry, following the methods of our group(178, 179). 
tRNA were purified from total RNA preparations extracted from transformed 
HEK293T and HeLa cell lines by HPLC (Figure 3-12A). tRNA were isolated 
from each sample and quantified. Less than 2 µg was obtained from samples 
T2-1#3b and T2-1#6. Nonetheless, all samples were processed and analysed 
by LC-MS for ribonucleoside composition. Except for T2-1#6, isolated tRNA 
proved to be over 90% pure by Bioanalyzer fluorescent electrophoresis, thus, 
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we expect little contamination from other cellular RNAs. LC-MS/MS analysis 
for 7 ribonucleosides (adenosine (A), guanosine (G), uridine (U), cytidine (C), 
m3C, m5C and 4-methylcytidine (m4C) ) were conducted. Each ribonucleoside 
is positively identified by aligning commercial standards by their retention 
times, accurate masses and collision induced disassociation fragmentation 
patterns.  
Instrument sensitivity and dynamic range was determined through external 
calibration curves for C, m3C and m5C. Injection to injection variance across 
sample runs was determined to be 18.9% though CV of spiked 15N5dA internal 
standards. Relative quantification for the m3C content in tRNA was 
determined by the normalized ratios of m3C: total AUCG or m3C: m5C.  
In the first serious of experiments, low levels of m3C (82-297 fmol/µg tRNA; 
limit of quantitation 5.62 fmol) was detected for in all samples, save for 
sample T2-#3+DKD, wherein no m3C signal was detected.  In all, relative to 
T2-1#1, T2-1#1b, T2-1#1c controls, A modest 22% decrease in m3C levels 
was observed in T2-1 #3 and T2-1 #3. A further 5% decrease was detected in 
T2-1#3+772. A complete loss of m3C signal in T2-#3+DKD were observed. In 
HeLa cells, relative to 830, which is a scramble shRNA control, a 26% 
reduction in m3C signal was observed in 772, which is Mettl6 knockdown and 
a further 8% loss was detected in triple knockdown. However, it was found 
one enzyme phosphodiesterase II was added at a much lower concentration 
compared with the previous protocol of our group (179), so a modified recipe 
was adapted.  
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After several rounds of experiments, METTL2A and 2B are found to 
contribute to about 40 % (±5%) of the m3C level in tRNAs (Figure 3-13A), 
while knocking down METTL6 contributes to approximately 12% (±5%). 
However, we haven’t find statistically significant contribution towards m3C 
formation from METTL8 (Figure 3-13B). To check those m3C contributions 
in mice, knockout mice for Mettl2, 6, 8 genes were created by Cas9/CRISPR 
and the sequence of KO loci was confirmed by genotyping and mRNA levels 
were checked by real-time PCR. Similar to human Mettl2A and 2B KO 
HEK293T cell line, Mettl2 KO showed around 40% reduction of m3C contents 
in tRNA/total RNA compared with WT, while Mettl6 KO showed around 20% 
m3C reduction (Figure 3-13D, E). m3C contents remains similar level between 
WT and Mettl8 KO, Mettl2 KO and Mettl2, 8 Double KO, Mettl6 KO and 
Mettl6, 8 Double KO, implying no contribution/little contribution of m3C 
modification from mouse Mettl8 (Figure 3-14D, E). Importantly, mRNA level 
of Mettl2, 6, 8 were checked in all kinds of KO and WT, and it indicates no 
upregulation of any Mettls in another one’s KO.  
To check if m3C is located within other RNA species, the fractions of 28S and 
18S rRNA, the two largest rRNA components were collected (Figure 3-12A), 
concentrated, digested and analyzed. We observe there is m3C signals, albeit 
much less abundant than in tRNA, as compared either to total AUCG area 
under curve, or the adjacent m5C peak’s area under curve (Figure 3-12C). We 
calculated the m3C/ total AUCG and m3C/m5C ratios across 20 samples, 
containing either WT or certain KO, and 9 samples are tRNA and 11 samples 
are total RNA (Figure 3-12E). 28S and 18S rRNA contributes a high 
percentage (>80% by UV signal Figure 3-12A) of total RNA, and 28S and 
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18S rRNA contains high levels of m5C. If there’s no m3C located in other 
RNA species besides tRNA, we would expect a much lower m3C/m5C ratio in 
those 11 total RNA samples. It implies m3C could reside within other RNA 
species such as mRNA, 5S rRNA, 5.8S rRNA, etc. The m3C signal seen in 
28S and 18S could come from long mRNAs (co-purified with 18S or 28S 










Figure 3-12. Size exclusion HPLC and typical chromatography of LC-MS/MS 
for m3C 
(A) Typical size exclusion HPLC chromatography, peaks for various RNA 
species are labelled. 






C (258.1-126.1 m/z) chemical 
standards and two tRNA samples analyzed. 
(C) Typical LC-MS/MS for 258.1-126.1 m/z chemical standards and three 
total RNA samples analyzed. 
(D) Typical LC-MS/MS for 258.1-126.1 m/z in 28S and 18S rRNA from WT 
and METTL2 or 8 KO. 
(E) m
3




C ratios across 20 samples, 9 







Figure 3-13. LC-MS/MS for quantitative m3C analysis in various RNA species 
(A) LC-MS/MS measurements of m3C RNA samples used in the assay, by 
normalizing against total C, m5C or 15NdA 
(B) m3C contents in tRNAs from HCT116 WT and Mettl8 KO cell line. 
(C) m3C level in METTL2 overexpressed cells 
(D) m3C contents in mice liver tissue.  
(E) m3C contents in mice whole brain RNA  
Error bars are for Biological triplicate, Student t-test; * p < 0.05;  ** p <0.01 
 
3.12 Identification of RNA species binding to METTL2, 8 by PAR-CLIP 
and validation by RIP, RT-PCR  
Photoactivatable Ribonucleoside Enhanced Crosslinking and 
Immunoprecipitation (PAR-CLIP) is a used for discover RNA binding 
proteins (RBPs)’binding sites on various RNA species. It uses photoreactive 
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ribonucleoside analogs, including 4-thiouridine (4-SU) and 6-thioguanosine 
(6-SG) as cell culture supplements. 365 nm UV light induces efficient 
crosslinking of RNA binding protein with photoreactive nucleoside-labelled 
RNA species. After immunoprecipitation of the RBP, cross-linked RNA was 
isolated, reversed transcribed into cDNAs, and deep sequenced using second 
generation sequencing. Flag-METTL8 is ectopically overexpressed in HeLa 
S3 cells and PAR-CLIP is performed at University of Chicago using Flag 
antibody. As shown in (A), 1095 peaks were identified for METTL8, and 
binding motif were calculated. However, the p-Value for the peaks are not as 
significant as a typical RBP, such as YTH domain family members, which are 
m6A binding proteins(180). Nevertheless, Gene Ontology Enrichment is 
performed to show transcripts which encodes nucleus structures, RNA binding 
proteins, etc. as top enriched clusters by using DAVID(181) , as shown in 
Figure 3-14 (B).  
 
Table 3-1 mRNA transcripts identified as binding partners of METTL8 by 
PAR-CLIP 
 
Gene ID Symbol Description binding 
sites 
90632 LINC00473 long intergenic non-protein coding RNA 473 4 
1003026
92 
FTX FTX transcript, XIST regulator (non-protein 
coding) 
4 
164045 HFM1 HFM1, ATP-dependent DNA helicase homolog (S. 
cerevisiae) 
3 
29123 ANKRD11 ankyrin repeat domain 11 3 
3376 IARS isoleucyl-tRNA synthetase  3 
7919 DDX39B DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B 3 
4643 MYO1E myosin IE 3 
29123 ANKRD11 ankyrin repeat domain 11 3 
3376 IARS isoleucyl-tRNA synthetase 3 
7919 DDX39B DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B 3 
100 
 
90632 LINC00473 long intergenic non-protein coding RNA 473 3 
554226 ANKRD30
BL 
ankyrin repeat domain 30B-like 3 
With at least three bindings sites and ranking from highest binding sites and 
confidence 
 
Due to high homologue of METTL8 with METTL2, top candidates for 
binding with METTL8 listed in Table 3-1 were tested by RIP using METTL2 
antibody Abmart1/2. As shown in Figure 3-14 (C) and (D), NEAT1, which is 
a long non-coding RNA, forming paraspeckles with NONO and SFPQ, is 
confirmed, so do IARS and threonine tRNA AGU. It is noteworthy that 
NONO and SFPQ is identified as protein binding partners of METTL2 by 





Figure 3-14 Validation of METTL2, 8 RNA binding species identified by 
PAR-CLIP  
The antibody (Ab) used in the RIP are summarized in the table at the bottom.  
 
3.13 METTL2 could methylate itself in vitro 
Besides primer extension assay and Mass Spectrometry in finding substrates 
for RNA/DNA MTase , direct in vitro MTase assay could test if the suspecting 
protein is a MTase towards certain RNA substrates. The reaction is set up by 
incubating recombinant proteins, with its potential substrates, and isotope 
labelled S-adenosylmethionine, which is usually C14 or H3 labelled S-
adenosylmethionine (14C-SAM, or 3H-SAM), resolved on denaturing Urea gel 
and exposed using autoradiography. Although rarely used, a good example is 
finding DNMT2 as a tRNA MTase, instead of being a DNA MTase like its 
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close paralogs, DNMT1 and DNMT3(182). DNMT2 is shown be able to add 
methyl group from S-adenosylmethionine towards tRNA from Dnmt2 KO 
cells. To test if METTl2 could methylate tRNAs from Mettl2 KO cells, a 
similar assay was done following the methods for DNMT2(182). However, In 
Figure 3-15 (A) & (B) The bands in the lower part of the gel turns out to be 
METTL2 itself, since the bands are still there without add RNA from either 
WT or KO cells. Similar results were obtained using GST tagged proteins as 
shown in (C) or using 14C labelled S-adenosylmethionine as shown in (D). 
Indicating recombinant METTL2 could add 3H-labeled methylgroup towards 
protein itself, instead of the tRNAs. 
It is not surprising a potential RNA/DNA MTase could methylate itself in 
vitro, since in vitro reactions creates a highly concentrated environment for 
proteins and many recombinant Methyltransferase could show 





Figure 3-15 METTL2 could auto-methylate itself in vitro 
(A) In Vitro MTase assay using FPLC purified recombinant METTL2B 
proteins, with RNA from either scramble shRNA transfected cells or Mettl2, 6, 
8 stable knocking down cells. EtBr staining of RNA is at upper panel, 
autoradiography is at lower panel. 
(B) Repeat of another batch of His tagged METTL2 proteins in in Vitro 
MTase assay, no RNA was added in lane 6. 
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(C) Repeat of (A) and (B) by using purified GST tagged METTL2 proteins. 
(D) Repeat of in vitro MTase assay using C14-labelled SAM, using histone 
H2A methylated by PRMT5 and C14-SAM as control. 
 
3.14 Identification of METTL2, 6, 8 protein complex by Flag-IP mass 
spectrometry 
To elucidate the protein complex formed in vivo, FLAG tagged Mettl2, 6, 8 
vectors were constructed and transfected into HeLaS3 cells and after 
puromycin selection, several stable cell lines were generated. 
Immunoprecipitation using FLAG antibody were performed against various 
cell lysate, and the IP mixture were separated on SDS-PAGE and sent for 
Mass spectrometry.  
Proteins which are of high confidence or verified by reverse IP or flag IP again 
were shown in Table 3-2. As shown in Figure 3-16 (A), Seryl-tRNA 
synthetase was identified the only high confidence partners with METTL6, 
while NONO-SFPQ, some eEF3 were found in complex with METTL2 and 
METTL8. Seryl-tRNA synthetase raised great interest since it is one of the 
twenty amino-acryl syntheses which specifically interact with seryl-tRNA and 
aminoacylate serine tRNAs. Moreover, METTL2A and 2B were just found to 
target threonine tRNAs, and the other only known tRNA species which bear 3-
methylcytosine is tRNA serine and arginine in cytoplasm, and tRNA serine 
and threonine in mitochondria. This interaction is confirmed by Flag-IP, 
followed by Western Blot. The finding of METTL6 interact with SARS may 
imply tRNA serine could be the substrates of METTL6, although not 
confirmed by primer extension assay, as shown in Figure 3-7, no difference 




Table 3-2 METTL2, 6, 8 protein complex identified by Flag-IP Mass Spec 
Flag tagged Bait Binding Partners 
Mettl2A,2B SFPQ, NONO, Nucleolin, EF1A1, EF1A2, EF1A3, HNRPK 
Mettl6 SARS, MEP50, ICLN(Methylosome subunit pICln) 
Mettl8 SFPQ, NONO  
Proteins in bold are verified by Flag IP, Western Blot 
3.15 METTL6 interact with Seryl-tRNA synthetase (SARS) in a RNA 
dependent manner 
To validate the Mass Spec finding, FLAG IP were performed against cell 
lysate which has overexpressed FLAG-METTL6 and FLAG-METTL6-∆SAM. 
FLAG-METTL6 interacts with endogenous SARS, as consistent with Mass 
Spec finding, while FLAG-METTL6-∆SAM failed to show the interaction. To 
further narrow down the region responsible for the interaction between SARS 
and METTL6, a series of truncations were made for GST tagged SARS 
protein, which has 1-172 amino acids, 1-152 amino acids, 153-460 amino 
acids, 153-514 amino acids of SARS, all counted from the N terminal of 
SARS. Intriguingly, only endogenous SARS were immunoprecipitated by 
FLAG-METTL6, while all the truncated SARS failed to bind full length 
METTL6, which may indicated either there are multiple domains required on 
SARS or the tertiary structures is of critical importance in recognizing 
METTL6, see discussion.  
Given the fact that SARS interact with tRNA serine, a hypothesis that SARS 
and METTL6 may interact through tRNA serine. IP mixture were digested 
with RNase A or DNase I before the washing steps and resolved on SDS-
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PAGE. Interestingly, the binding between SARS and METTL6 are lost upon 
RNase incubation, but not DNase treatment. These results indicates SARS 
interacts with METTL6 in a RNA dependent manner, although the identity of 
the RNA species has not been confirmed as serine tRNA. The failure of using 
primer extension to test 3mC at position 32 in serine tRNAs also render the 
substrates of METTL6 elusive. 
The interaction between METTL6 and SARS’s inspired the hypothesis that 
METTL2A, 2B may interact with Threonyl-tRNA synthetase. However, the 
FLAG IP towards METTL2 Overexpressed cells failed to discover TARS as 




Figure 3-16 METTL6 interact with seryl-tRNA synthetase (SARS) in a RNA 
dependent manner 
(A) Commassie blue staining for FLAG immunoprecipitated mixtures from 
FLAG only and FLAG-METTL6 ectopic expressed cell lysates, the boxed 
regions are sent for Mass Spec.  
(B) FLAG-IP from cells which overexpress FLAG only vector, 
FLAG_METTL6 and FLAG-METTL6-∆SAM and blot against SARS 
(C) Flag IP in either METTL2 or METTL6 overexpressed cells 
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(D) Expression check of several GST tagged-truncated SARS proteins  
(E) FLAG-IP in cells overexpressed of various GST tagged-truncated SARS 
proteins  
(F) Treatment of FLAG-IPed mixture with or without RNase, DNase and blot 
against FLAG (for IP quality check,) and SARS, check lysate for ectopic 
protein expression levels by blotting against SARS and β-Actin 
 
3.16 METTL2, 6, and 8 in global translation 
Due to the potential link between certain tRNA modifications and translation. 
Polysome profiling was performed to check if Knocking down or 
overexpression mutant METTL2, 6, 8 would affect global translation. Of note, 
each plate of cells should not be too confluent, otherwise it would lead to 
slowing down of translation machinery, thus caused biased results. Each 
sample presented in the Figure 3-17 were harvest at 70 % ~ 90 % confluence. 
Polysome profiling was performed to check if the knocking down or ectopic 
overexpression of mutant METTL2 family proteins would affect global 
translation. Cells in every profile were harvested at 70% to 90% confluence. 
All cells are grown in standard normal growth conditions (For most cell lines, 
it is DMEM high sucrose and 10 % FBS). There is no statistically significant 
difference between wild type and METTL2 KO clones (clone 3 and clone 7) 
for the polysome versus monosome area under curve (AUC) ratio (P/M ratio) 
(Figure 3-17A). In another study, knocking down of METTL2A and 2B 
induced a higher monosome peak and lower polysome peaks than control 
scramble shRNA groups. Moreover, knocking down or knock out METTL8 
also failed to show drastic difference with wild type control. However, 
overexpressing METTL8 ∆SAM mutant caused global down regulation of 
translation as shown by the higher monosome peak and lower polysome peaks, 
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indicating a role of METTL8 ∆SAM mutants in affecting global translation 
(Figure 3-17B). It could be possible that overexpression of METTL8 ∆SAM 
mutants would cause some cellular stress such as protein misfolding, or it 
could serve as dominant negative towards endogenous METTL8. Future work 
need to be done to clarify the difference between different cell lines. Moreover, 
Mettl6 or SARS would cause a global change in translation, as demonstrated 
by lower P/M ratio (Figure 3-17C,D). However, METTL6 single KO failed to 
show a significant downregulation of P/M ratio. In all, in all the cell lines we 
tested, we failed to observe a significant change in P/M ratio, indicating the 
function of METTL2, 6 and 8 remains elusive. 
As shown in Figure 3-17 (A), knocking down METTL2 (both 2A & 2B) 
affected a global translation by inducing a higher monosome peak and lower 
polysome peaks. Although the total area under curve (starting from 40S 
monosome peak and ending at the end of fractionation) is not identical 
between two samples in Figure 3-17 (A), there’s still a significant decrease in 
polysome fractions as compared in KD cells by normalizing each OD of 
METTL2 KD cells to WT. 
As mentioned in introduction, overexpressing mutant METTL8, or loss of 
METTL8 would cause up-regulation of ATM, at two fold up-regulation at 
mRNA level, but 5-10 fold up-regulation at protein level accessed by Western 
blot. To address mechanism for up-regulation of ATM, METTL8 WT and 
∆SAM mutant proteins were transfected into HCT116 cells. After puromycin 
selection and colony picking up, stable cells overexpressing METTL8 WT and 
∆SAM mutant were generated and proceeded to polysome profiling as shown 
in Figure 3-17 (B). Overexpressing METTL8 ∆SAM mutant caused global 
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down regulation of translation as shown by the higher monosome peak and 
lower polysome peaks, indicating a role of METTL8 ∆SAM mutants in 
affecting global translation apparatus. Moreover, Mettl6 or SARS knockdown 
would cause a global down regulation of translation machinery, as 
demonstrated by polysome: monosome ratio. Either Mettl6 or SARS KD will 
caused a lower polysome peaks and higher monosome peaks.  
However, a METTL8 KD or KO failed to show a similar pattern as METTL8 
∆SAM mutants, neither in some other METTL2/6 KO, indicating future work 




Figure 3-17 METTL2, 6, 8 could affect global Translation 
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(A) Polysome profiling comparing between cells stably expressing scramble 
shRNA and Mettl2 shRNA;  
(B) Polysome profiling comparing between cells stably expressing wild type 
METTL8 and METTL8 ∆SAM mutant;  
(C) Polysome profiling comparing between cells stably expressing scramble 
shRNA and Mettl6, Seryl-tRNA synthetase double shRNA; 
(D) Another experiments repeating (C)  
 
3.17 Loss of METTL2 confers higher sensitivity to translation 
inhibitors and one alkylation agent 
Measuring cell line’s viability, growth rates and sensitivity to chemicals that 
targets various cellular pathways are common themes for gene function studies. 
Cell growth rates were accessed by counting cell numbers using 
haemocytometer at different time points, or use MTS assay. In several cell 
lines tested ( 293T, HeLaS3, HCT116, and A172 cell lines), KD / KO 
METTL2 alone could confer reduced cell growth rates. Of note, A172 cell 
lines showed a much profound reduced growth rates upon Mettl2 KD, as 
shown in Figure 3-18 (A), so did HCT116, as accessed by colony formation 
assay as shown in Figure 3-18 (B).  Double KD of Mettl2 & 8 or a triple KD 
reduced the cell growth rates and viability more pronounced in HCT116 and 
HeLaS3 cell lines. 
Due to the sensitivity of ABP140 KO strain to neomycin and 
ABP140&TRMT1 Double KO to CHX(115), sensitivity of METTL2, 6, 8 
KD/KO to both drugs were performed by MTS assay; A172 cells showed a 
higher sensitivity to Geneticin and CHX, as shown by MTS assay, as in Figure 
3-18 (C). However, the effects are not statistically significant in some other 
cell lines, which need more thorough investigation. 
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ABP140 KO yeast showed a significant higher sensitivity to MMS alkylation 
damage(117). To test if this is true in mammalian cell lines, MMS treatment 
plus MTS assay were performed and indeed, Mettl2, 8 double KD and Mettl2, 
6, 8 triple KD showed a higher sensitivity to MMS at various concentrations 
ranged from 1 mM to 5 mM, comparable to similar window in yeast. 
It is of note that only repeatable results were shown in Figure 3-18. Further 
studies in more cell lines or Mettl2, 6 KO mice are needed support those 
phenotypes observed 
 
Figure 3-18 Loss of METTL2, 6, 8 confers higher sensitivity to translation 
inhibitors and alkylation damages 
(A) Representative growth curve shows loss of METTL2 confers lower 
growth rate in 293T cell line; 
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(B) Representative colony formation assay comparing control knockdown and 
METTL2 stable knockdown  
(C), (D) and (E): MTS assay to assess sensitivity to Geneticin (Gibco), which 
is an analog to neomycin, Cycloheximide and MMS; 
(*** indicate p value < 0.005, ** indicates p value < 0.01, * indicates p value 
< 0.05, student T tests) 
 
3.18 Codon-run to study effects of 3-methylcytosine on translation 
Inactivation of certain tRNA modification enzymes can impair translational 
decoding process, as measured by decreased translation of relevant 'codon-
runs' from several publications (183, 184). To investigate the possible effects 
of the loss of 3-methylcytosine observed in the METTL2 KO cells, reporter 
plasmids were constructed, containing both Renilla luciferase (Rluc; internal 
reference) and firefly luciferase (luc2) genes, in which luc2 translation, but not 
Rluc translation, depends on in-frame translation with a codon-run of five or 
ten identical codons(183, 184).  
Making Codon-run reporter constructs: pEF6 vector is inserted with codon 
optimized Renilla luciferase (Rluc) and Firefly luciferase (luc2) cloned from 
pMirGlo of Promega using oligos listed in the Table below, with stop codon 
for Renilla luciferase excluded. Renilla luciferase was inserted into pEF6’s via 
KpnI and BamHI RE sites located at Multiple cloning sites while firefly 
luciferase was inserted using EcoRI and NotI, thus leaving 5’-ACT AGT CCA 
GTG TGG TG-3’ linker located between Renilla luciferase and Firefly 
luciferase. 








Runs of codons matching the anticodons of several human tRNAs which is 
approved or suspected to have m3C were generated by annealing DNA oligos 
containing BamHI/EcoRI overhangs at either ends and harboring five or ten 
successive, identical Threonine, Serine, or Glycine/Serine codons or Control 
codons, and inserted between the BamHI and EcoRI sites downstream of the 
Rluc and upstream of luc2. The luc2/Rluc ratios obtained from control cells or 
Knockdown/Knockout cells were determined using luciferase assay, which 
used passive lysis buffer according to manufacturer’s instruction (Promega’s 
Dual Luciferase kit) and measured manually.  
(ACN)10 and (UCN/AGY)10 indicate runs of 10 identical threonine and 
serine codons, respectively, and are translated in frame with firefly luciferase 
(luc2). Reporter constructs containing the indicated codon runs, were 
transfected into WT or METTL2 KO cells. The ratio between luc2 and Rluc 
was obtained and used to calculate the efficiency of translation of the codon 
run. 
However, the differences between METTL2 KO and WT were generally 
negligible, showing that the altered m3C modification pattern of METTL2 KO 
tRNAs have little effect on translation efficiency in this experimental system. 
Nevertheless, it is noteworthy that the absolute luminance difference between 
WT and Mettl2 KO regarding threonine codons and Scramble shRNA, SARS 
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KD, Mettl6 KD is obvious, as shown in the Figure (B) and (C) below.  Since 
Renilla luciferase harbours several threonine AGU/UGU and serine codons, it 
is not surprising that there is a difference in absolute readings for both 
luciferase between WT and KO.  
 
Figure 3-19 Codon-run to study effects of 3-methylcytosine on translation 
(A) Diagram of Codon-run reporter constructs, which is cloned from 
pEF6/V5-His A vector, driven by the pEF1α promoter 
(B) Threonine codon-runs, 10 seconds’ absolute readings of firefly luc2 and 
Renilla luciferase are shown in the left and middle panel, with ratios of 
luc2/Rluc on the right panel, comparing 293T Mettl2 WT and KO, cells are 
seeded at same density and transfected with vectors for 24 hours 
(C) Serine codon-runs, 10 seconds’ absolute readings of firefly luc2 and 
renilla luciferase are shown in the left and middle panel, with ratios of 
luc2/Rluc on the right panel, comparing HCT116 Control KD, Seryl-tRNA 
synthetase KD, and Mettl6 KD, cells are seeded at same density and 




3.19 Phylogeny and structural analysis tRNA 32-38 pair  
The anticodon loop of tRNA is universally conserved to contain seven 
nucleotides and is important in interacting with other proteins or RNA, such as 
ribosome or amino-acyl tRNA synthetase. As introduced in section 1.7, the 
32-38 base pairs located at the junction of anticodon stem and loop, it is 
shown in some tRNAs, the 32-38 pair has contact with ribosomal RNA to 
ensure uniform tRNA binding to the A site and play a role in discrimination of 
synonymous codons and reading frame maintenance at P sites. Thus, the pair 
extends the sequence properties of the anticodon loop in addition to the 
usually modified purine at 37 and the U-turn at position 33.  
Phylogenetic analysis was performed using a tRNA database (11), its design 
allows user to get numbers of tRNA with specific nucleotide at position 32 
and position 38 by typing in, for example, C*****A (* indicates any 
nucleotide) query into the database, thus a specific number of this kind of 32-
38 pair out of all tRNAs for different domain of life, or certain species, or 
certain tRNA isoacceptors are obtained. As shown in the Table 3-4 below, 
32(Cytidine or modified cytidine)-38(Adenosine) base pair outnumber other 
base pairs in all three domains of life. However, by taking a closer look at 
Threonine tRNAs, it is noteworthy that Cytidine (32) - Adenosine (38) pair on 
threonine tRNAs has a much higher percentage in Eukaryotes than in either 
Bacteria or Archaea. In fact, all human threonine tRNAs has cytosine and 
adenosine at position 32 and 38 respectively, based on the tRNA database(11), 
while threonine tRNA in E. Coli all have U-A pair at 32-38 positions, 
indicating a difference in tRNA anticodon stem loop during evolution and 
natural selection.  Moreover, all human threonine tRNAs has uridine and 
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adenosine at position 33 and 37, thus human threonine tRNAs all have 
CU***AA at anticodon loop (*** indicates anticodon).   
Based on the Table 3-4 and Table 3-5, and from previous studies(125), 
approximately 90% of the 32-38 oppositions can be classified to two families, 
in which each pair are isosteric towards each other, one with a larger (approx. 
86 %, including 32C-38A pair) and the other with a smaller (approx. 7 %) 
population. The remaining (approx. 7 %) of the pairs have been grouped to a 
3rd family, since they cannot be designated into the first two. Of note, the 
Y(pyrimidine)32-R38 base-pairs are not isosteric upon base pair reversal, may 
provide a structural explanation for the conservation of pyrimidine at position 
32.  
Table 3-4 tRNA 32–38 base pairs frequency in three domains of life 
 
*calculated from tRNA database(109) 
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Table 3-5 Threonine tRNA 32–38 base pairs frequency in three domains of 
life 
 
*calculated from tRNA database(109) 
For structural analysis tRNA 32-38 pair, based on the available sequences and 
crystal structures, it is demonstrated the relatively conservation of a bifurcated 
hydrogen bond interaction between residues 32 and 38 located at the 
stem/loop junction in most of the tRNAPhe (12). This interaction leads to the 
formation of a non-canonical base-pair Figure 3-20 (A) .  
However, a few exceptions are discovered for this bifurcated hydrogen bonds 
by searching available PDB structures. For example, one tRNA/synthetase 
complex between threonine tRNA synthetase (TARS) and tRNA threonine 
from E. Coli (Protein Data Bank: 1QF6) showed the U-A pair is impaired 
upon aminoacyl-synthetase binding. As shown in the Figure 3-20 (D), the 
uridine residue is interacting with one asparagine residue from TARS, 
indicating a potential tRNA conformation change upon aaRS interaction.  
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Another example is from PDB entry 1EIY, in which Cytosine and Adenosine 
no has polar interaction between each other.  Moreover, cytosine is bonding 
with N atom at 3’ position instead of the oxygen atom on the pyrimidine ring 
of cytosine in PDB entry 3WC2. Strikingly, 32 Cytosine interact with 37 
adenosine instead of 38 adenosine in several arginine tRNAs ( PDB 2ZUE and 
2ZUF )  
These examples searched from PDB and presented Figure 3-20 (B-F) further 
demonstrated the pairing diversity of 32C-38A pair in various structures. In all, 
the extended sequence signature by 32-38 nucleotides at the junction of the 
anticodon loop and stem underscores the importance of both nucleotides. 
Lacking of tRNA structures with 3mC calls for further functional and 





Figure 3-20 Interaction between tRNA Residue 32 and 38 extracted from 
solved structures 
Each stick diagram is extracted from one PDB accession file indicated below 
each diagram. Carbon: Green; Nitrogen: Blue; Hydrogen: White (only some of 
the polar hydrogen shown); Oxygen: Red; Phosphor: Orange. 
(A). C-A pair at 32-38, notice the pair occurs between O atom on cytosine and 
N atom on adenosine; 
(B). C-A pair at 32-38, notice the pair occurs between 3’ N atom on cytosine 
and N atom on adenosine;  
(C). No polar interaction between C-A pair at 32-38;  
(D). 32 Uridine may interact with protein in complex, such as TARS 
(E) & (F). 32 Cytosine interact with 37 adenosine instead of 38 adenosine, 
phosphate backbone is shown in orange ribbons in (F) 
 
Table 3-6 Summary of each 32-38 pair in the Figure 3-20 
PDB 
Accession 





1EHZ Phe Cm A O N Baker's Yeast 
2IY5 Phe C A O N Th.Thermophilus 
3TUP Phe Cm A O N Human mito 
1OB5 Phe Cm A O N Bacteria 
3WC2 Phe C A N N C. albicans 
1EIY Phe C A - Th.Thermophilus 
       
1QF6 Thr U A - E. Coli 
       
1F7V* Arg C A - Baker's Yeast 
2ZUE* Arg C A - Pyrococcus 
horikoshii 




- no polar contacts between 32 and 38 bases   





4 CHAPTER 4. DISCUSSIONS AND FUTURE WORK 
The chapter will present the limitations of some of the methods used and  
some of the results obtained, besides discussing the scientific achievements 
from this thesis project. Ongoing or future work is also to be described in the 
chapter. 
4.1 Limitation of Primer Extension assay 
Despite many advantages as shown in the introduction 1.2.1 and results 3.5, 
the use of reverse transcription for detection of modified nucleotides in RNAs 
is not very straightforward. In fact, the reverse transcription profile, even for 
an unmodified RNA, depends on several parameters, especially the presence 
of Pyrimidine - A (C–A and U–A) bonds, which are very sensitive to nuclease 
cleavage (some commercial reverse transcriptase is a nuclease), and also on 
some RNA secondary structure which could also generate RT pauses / blocks. 
Therefore, the simple presence of a pause in a primer extension profile does 
not necessarily indicate the presence of a modified residue. In addition, 
reverse transcription profiles of modified RNAs are often prone to some kind 
of stuttering (doubling of the bands on the gel) at the modified residue that 
blocks the reverse transcription (Figure 1-2) (61, 185). The reasons for such 
stuttering remains unclear, but this possibility complicates the detection of 
nearby modified residues and should be considered during analysis of reverse 
transcription patterns.  
It is indeed the case for primer extension assay for tRNAs other than threonine 
tRNAAGU or tRNAUGU. Indeed, the appearance of pauses in an RT profile may 
only serve as an indication of the possible occurrence of modified residues at 
these positions. The use of other complementary techniques of RNA analysis, 
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such as HPLC and Mass Spec will serve as ultimate ways to confirm the RT 
results.  For primer extension shown in the results 3.5, 20 centimetre gels were 
used, which is typically used for EMSA experiments. Ideally, a 40 centimetre 
sequencing length gel should be used to generate a lane pattern at single 
nucleotide resolution. 
4.2 Limitation of RIP assay 
PAR-CLIP has been used by one group to identify binding partners for 
NSUN6 (186), in which Flag IP of Flag-tagged NSUN6 showed a significant 
higher percentage binding towards tRNAs than Flag only vectors, thus leading 
to identifications of certain tRNA species as substrates for NSUN6. 
RIP assay is commonly used to validate the RNA species which is found to 
bind to RNA binding proteins by PAR-CLIP. However, good negative control 
and optimization of washing steps should be performed to exclude non-
specific binding. Ideally, antibody which can target endogenous protein of 
interest should be used in RIP, instead of using anti-tag antibody to immune-
precipitate ectopic overexpressed proteins. Indeed, generation of bands using 
primers targeting GAPDH mRNA, which indicates a potential non-specific 
binding in RIP assay. Future PAR CLIP or more validation need to be 
performed to address this issue. 
4.3 Limitation of ribosome profiling 
Thought ribosome profiling has not been finished before the submission of 
this thesis. Limitations and cautions are discussed below for future reference. 
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4.3.1 Issues in analyzing ribo-seq together with parallel RNA-seq  
Transcriptional or post-transcriptional processes will modulate the abundance 
or dynamics of the polysome-associated RNA by controlling mRNA. It is 
therefore essential to include mRNA abundance data when analysing ribosome 
profiling data. RNA-seq for cytoplasmic or whole-cell mRNA are usually 
obtained in parallel to allow for such corrections. In the past, translational-
efficiency scores calculated as the log2 ratio of the amount of polysome-
associated RNA or RPFs to the amount of cytosolic RNA were used to 
determine translational activity of an mRNA. However, analysis based on 
translational-efficiency scores showed poor correlation. The analysis of 
translational activity (ANOTA) was developed and its results correlate well 
with changes in protein amounts (187, 188).  A third method called 'RPF-
based' method has been developed for the analysis of ribosomal profiling 
(189), (190), However, the performance of this method in monitoring changes 
in the proteome has not been studied. In all, better analytic methods should be 
developed and curated for studying polysome profiling data (191).  
4.3.2 Sample harvest issues  
One highly concerned issue for ribosome profiling is the extent to which the 
cell harvest and lysis procedure may distort the ribosome distribution. Unless 
the material can be cooled to near 0°C extremely rapidly, polysome run-off 
will occur, depleting ribosomes from all initiation sites, all short ORFs and the 
5′-proximal part of long ORFs (192). 
To avoid this, many protocols would incubate the cells with CHX for 5 to 10 
min before cooling down. This prevents ribosome run-off, but it will give 
much more footprints at initiation sites than at steady state, because CHX 
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doesn't inhibit scanning or initiation, and so an additional 80S initiation 
complex can be added to every mRNA which has a vacant initiation site at the 
time when the inhibitor starts to “bite.”. For highly efficient sites that capture 
virtually all scanning ribosomes, it is estimated that 100% occupancy of 
vacant initiation sites will occur within <10 seconds of the onset of inhibition 
by CHX. It follows that if an initiation site is mutated to be so inefficient that 
it captures only 10% of scanning ribosomes, 100% occupancy of all vacant 
sites will still be achieved in < 2 min after the onset of inhibition. So a 3 to 5 
min incubation with CHX could result in footprints of equal magnitude at 
initiation sites that really differ in intrinsic efficiency by a factor of 10 or more. 
Added to this, there is a polarity effect in that an 80S ribosome stalled at a 5′-
proximal site will prevent any subsequent scanning ribosome from reaching 
downstream sites, and this could result in the observed footprint signal at a 
uORF initiation site with mediocre context actually being greater than the 
signal at a highly efficient downstream start site (192). 
It would be a similar situation arise if cells are incubated for 3-5 min with 
harringtonine, which inhibits neither initiation nor on-going elongation (or 
polysome run-off), but block the transition from initiation to elongation, so 
that it leaves clear footprints of 80S ribosomes stalled at every initiation site. 
This has proved to be an excellent way of identifying initiation sites, but, like 
CHX, it can completely obscure their relative utilization frequency under 
steady state. 
4.3.3 Other cautions in analyzing ribosome profiling 
The precise positions at which ribosomes are associated with the mRNA could 
be located after the alignment of RPFs to the reference genome. This unique 
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property has been employed for detailed mechanistic studies on nearly every 
in translation process, including the initiation, elongation and termination.  
Moreover, ribosome profiling in embryonic stem cells has shown noncoding 
RNAs binds to ribosome, which suggests that non-coding RNAs could be 
translated into short peptides. However, this finding was re-analysed (193) and 
found that RPF sequencing obtained reads alone are not sufficient to judge if 
an RNA is translated or not. More recently, data obtained with cells treated 
with harringtonin, were insufficient for the prediction of whether an RNA was 
translated or not.  
Of note, many RNA binding proteins could protect, or partially protect its 
binding RNA species from nuclease digestion. Highly versatile RNA 
structures may offer another line of defence against nuclease digestion. Both 
issues should be evaluated when ribosome profiling data are used to study 
translation process. 
 
4.4 Self-methylation properties of METTL2, 6, 8  
As shown in Figure 3-15, the high self-methylation activity by recombinant 
METTL2, 6, 8 indicates certain residues of those proteins could be methylated 
and it is determined by mass spectrometry under the help from Prof. Zhao 
Yinming’s lab at Shanghai, China. Protein methyltransferase usually exhibit 
methyltransferase activity towards only one kind of amino acid residue 
However, both arginine and lysine residues are methylated in the case of mice 
METTL2 and METTL6, as shown in Figure 4-1A,B,C. Interestingly, R129 
residue in mice METTL6 is conserved to R225 in METTL2, but absent in 
127 
 
METTL8. As mentioned in 3.13 METTL2 could methylate itself in vitro, it is 
possible for a RNA/DNA MTase to methylate itself in vitro, since in vitro 
reactions creates a highly concentrated environment for proteins, co-factors 
and substrates and many recombinant Methyltransferase could show 
automethylation activity in vitro, such as PRMT5, even its canonical 
substrates are histone 3. 
 
Figure 4-1 Methylation sites identified by mass spectrometry 
(In collaboration with Prof. Zhao Yinming, Shanghai) 
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(A) (B) (C). Mass spectrometry identified several lysine (K) or arginine (R) 
residues being methylated in mouse METTL2 and METTL6. The methylated 
residues are indicated above the diagram for METTL2 or METTL6. (D) 
Residue R129 in METTL6 is conserved to R225 in METTL2, but it is absent 
in METTL8 
 
4.5 Methyl group on polar contacts 
In a methyl group, carbon is linked to three hydrogen atoms. Carbon is more 
electronegative than hydrogen. So carbon pulls bonded electrons nearer to 
carbon and carbon acquires a slight extra negative charge and those 
correspondingly hydrogens lose hold over bonded electrons and acquires a 
slight positive charge. Thus carbon get a little more electronic charge and it 
will push electrons towards the group to which it is linked.  
Thus methyl group will be electron releasing or electron donating compared to 
hydrogens, thus they act to prevent the carbon from absorbing some of the 
excessive negative charge of the conjugate. In an ethyl group (CH3-CH2-), this 
effect will be more pronounced than methyl group. The net electron releasing 
effect of ethyl group is more than that of a methyl group. For example, a 
tertiary carbon in a tertiary alcohol can absorb less negative charge since it has 
more methyl groups than a primary alcohol. 
4.5.1 Methyl group on N3 cytosine may introduce a transient positive 
charges upon protonation 
There are three naturally occurring modified nucleotide that could be 
introduced a transient positive charges(43): 1-methyladenosine, 3-
methylcytidine and 7-methylguanosine in cells, although this study has not 
been thorough(43). Simple methylation of one of the heterocyclic ring 
nitrogen of either the purine or pyrimidine base can result in a positively 
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charged quaternary nitrogen. Approximately, 25% of tRNAs harbours m1A+ 
at position 58 at TΨC stem-and-loop domain, and approximately 40% have 
m7G+ at position 46 of the variable arm. 
However, neither of both mononucleosides carries a net charge under 
physiological conditions. The m1A tautomer prevalent at pH 7 has no net 
charge and m7G is a zwitterion. It is tertiary structure of the molecules around 
the nucleosides that protonated modified nucleosides since NMR analyses of 
native, but 13CH3-enriched yeast and E. coli tRNAPhe demonstrate that the two 
methylated nucleosides are positively charged in the tRNA(194).  
Protonation occurs through tertiary structure hydrogen bonding, m1A58 to 
T54 and m7G46+, to G22, and C13. Thus, the purpose of methylations at A58 
and G46 in tRNAs is thought to produce site-specific electrostatic charges 
within the tertiary structure of the tRNA and not to add methyl groups to the 
molecular structure. The positive charges are transient because of their 
dependence on the weak tertiary interactions that can easily be disrupted by 
interaction with a protein. The study of other charged nucleosides has not been 
as thorough. With H-bonded tertiary interactions similar to those of m1A +, 
the nucleoside m3C+ would be positively charged. Thus, methylation of the 3’ 
position of C has the analogous property of introducing a transient Positive 
charge(43).  
4.5.2 3’ Methyl group on cytosine will increase the pKa of pyrimidine 
ring 
It is noteworthy that a roughly 4 % of Cytosine at the position 32 is 
methylated, and thus protonated(125).  Adding a methyl group at 3’ position 
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on cytosine would increase the pKa value of cytosine, it is proposed that a 
closer pKa value between electron donor and acceptor would increase the 
strength of hydrogen bonds(195). Thus, adding a methyl group at 3’ position 
will decrease the hydrogen bond strength formed by its adjacent O atom. 
Meanwhile, it is the adding of a methyl group at 3’ Nitrogen, which increase 
the pKa of the pyrimidine ring that render 3-methylcytosine protonated under 
physiological conditions. The protonated 3-methylcytosine could serve as an 
additional hydrogen bond donor at 3’ position on the pyrimidine ring. 
3-methylcytosine may affect some C-A pairing by a steric clash, based on the 
solved structures at tRNA 32-38 pairs as shown in the Figure 3 19 (A). Those 
Cytidines have polar contact with adenosine through 2’ Oxygen on C to 
Nitrogen on A, indicated as. O…H-N.  However, there are some exceptions, 
i.e. 3WC2, in which cytidine bonds adenosine through 3’ N atom. It is easy to 
anticipate that a methyl group on the 3’ N atom would create a steric 
hindrance which could disrupt the hydrogen bonds in certain C(32)-(A)38 pair. 
Cytosine modifications shows an example of modifying nucleobase to 
optimize RNA triplex forming. The natural RNA modification has inspired 
chemists to create man-made modified nucleobase to optimize RNA triplex 
forming in many biological and biotech applications. Regarding C•G-C 
(Figure 4-2 (A), (B)), because of the relatively low pKa (about 4.5) of 
monomer Cytosine, a low pH is required to fully protonate cytosine in a 
triplex-forming Peptide nucleic acid (PNA) to form a C+•G-C base triple.  A 
neutral PNA Nucleobase pseudoisocytosine (J), Figure 4-2 (C), has been 
synthesized to form a J•G-C base triple(196). The pKa of the J monomer is 
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about 9.4 and incorporation of J residues in a PNA significantly alleviates the 
pH dependence for PNA•RNA2 triplex formation(197). 
A PNA nucleobase 2-aminopyridine (M) in Figure 4-2 (B) with a monomer 
pKa of 6.7 is promising for the recognition of a Watson–Crick G-C pair to 
form an M+•G-C base triple(198). The replacement of cytosine residues by M 
residues allows the formation of stable and sequence-specific PNA•RNA2 
triplexes at near-physiological pH conditions(197). 
 
Figure 4-2 Nitrogen methyl group on polar contacts 
Adapted from(197) 
(A) Major-groove base triples of U·A-U (a), s2U·A-U (b), C+·G-C (c), and 
U·G-C (d). Notice in C+·G-C, the hydrogen bond formed between protonated 
N3 in cytosine and N7 in G is indicated by a red dashed line. The H, C, N, O, 
and S atoms are shown in white, cyan, blue, red, and yellow, respectively. 
(B) Major-groove base triples formed between peptide nucleic acid (PNA) 
bases (blue) and RNA Watson-Crick base pairs (black). Red dashed lines 
indicates hydrogen bonds formed between protonated 3’ Nitrogen in C+ and 
N7 in G, and protonated N1 in M+ and N7 in G. J is for pseudoisocytosine. M+ 
is for the protonated form of 2-aminopyridine. L is for thio-pseudoisocytosine. 
In the base triple L·G-C, the van der Waals interaction between the sulfur 
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atom of L and H8 atom of G is indicated by a green dashed line. Other 
hydrogen bonds between the bases are indicated by grey dashed lines. 
(C) Proposed effects by the methyl group at N3 position of the pyrimidine ring 
on cytosine. 
 
4.6 Enrichment of threonine tRNAAGU and tRNAUGU isoacceptors in 
eukaryotes 
The concentration of each tRNA is determined by its number of gene copies in 
the genome(199). Thus, tRNA gene copies correlates well with tRNA 
isoacceptor abundances and thus able to play a key role in affecting codon 
translation efficiency. Therefore, the study of tRNA gene content bias may 
help explaining codon usage biases in extant genomes. 
For any actively dividing cell, the translation efficiency of a given codon is 
determined by the amount of tRNA in the cell(200). The variability in tRNA 
gene number is extreme in some cases: certain tRNA species are absent in 
entire branches of the phylogenetic tree, whereas others are clearly 
predominant, e.g., there are no GGU threonine isoacceptors in the eukaryotes 
genome, and less than 5 copies of CGU isoacceptors, meanwhile, there are no 
GGA, ACU, serine tRNA isoacceptors, and less than 5 copies of CGA 
isoacceptors. 
Using principal component analysis, tRNA isoacceptors that became 
positively selected (increased in number) in Bacteria and Eukarya were 
identified(201). The results indicate that the appearance of UMs and 
hetADATs contributed to the divergence of eukaryotic and bacterial genomes 
from their archaeal counterparts. The effect of the Inosine 34 in eukaryotes 
and xo5U34 in bacteria caused by these enzymes increased the decoding 
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capacity of modified tRNAs which, therefore, were positively selected during 
evolution(201). The diverse codon usage biases displayed by Bacteria and 
Eukarya are, at least partly, due to the different modification strategies used to 
improve translation efficiency. However, other modifications have not been 
taken into calculation, and certain modification and the extended anticodon 
hypothesis may support other modification’s role in Unequal Enrichment of 
tRNA Isoacceptors in different Kingdom.  
 
Figure 4-3 Enrichment of some codons and tRNA isoacceptors in Eukaryotics 
(A) tRNA gene copy numbers in Bacteria and Eukarya, adapted from (202), 
different colors around codons different copy number of tRNAs  
(B) Human codon percentage, adapted from(171)  




4.7 Future work for identification of all substrates and modification sites 
by METTL2 family proteins 
As presented in the results, only threonine tRNAAGU and tRNAUGU 
isoacceptors have been confirmed as substrates for METTL2. Other 
modification sites have been elusive, as indicated from the mass spectrometry 
data and Figure 3-12, Figure 3-13. 
It is difficult to use primer extension to find every modification site for 
METTL2,6,8, since many of the probes for primer extension shows a stutter 
pattern and it requires a tremendous amount of work. Alternatively, m3C-seq 
has been planned to be able detect all 3-methylcytosine sites by comparing 
WT or METTl2, 6, 8 KO cells, which could be easily developed from the 
methods used from global profiling pseudouridine (Ψ) (38, 39). 1-
methyladenosine seq to profile all possible m1A sites in tRNA, rRNA (Poster 
at 2015 RNA editing Gordon conference and personal communication). A 
similar approach has been applied towards m3C. 
Single molecule real time sequencing (SMRT) offers another way to profile 3-
methylcytosine in whole genome or transcriptome. SMRT is a single molecule 
DNA sequencing method, in which a single molecular of DNA polymerase 
enzyme is fixed at the bottom of a zero-mode waveguide (ZMW) with a single 
molecule of DNA as a template(203). Four different fluorescent dyes is 
attached to one of four DNA bases. The fluorescent tag is cleaved off and 
diffuses out of the observation area of the ZMW, when a nucleotide is 
incorporated by the DNA polymerase, with a detector monitoring the 
fluorescent signal of the nucleotide incorporation(203). 
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This third generation sequencing technology has been utilized to discover a 
broad spectrum of DNA base modifications, such as 5-methylcytosine (m5C), 
6-methyladenine (m6A), N4-methylcytosine (m4C), etc (as shown by Pacific 
Biosciences webpage). in which variant enzyme kinetics identify modified 
DNA bases. Of note, six human Pols belonging to the three families: B (Pol δ), 
X (Pols β and λ) and Y (Pols κ, ι and η) have been compared for the properties 
to read through 3-methylcytidine. It was shown that m3C would impair B-
family, block X-family, but not Polymerases in Y-family. Although both Pols 
η and ι could install nucleotides opposite m3C, they could introduce erroneous 
dATP and  dTTP, respectively. Meanwhile, Pols κ and η are most efficient in 
extending m3C base-paired primers. In conclusion, the presence of functional 
Pol η is mandatory to efficiently overcome 3-methylcytosine (m3C) by 
mediating complete bypass or extension.  In future, protein engineering could 
use the natural properties of Pols such as Pols η, or alter the properties of 
natural DNA polymerase to map m3C transcriptome wide using SMRT. 
4.8 Future structural study of METTL2 family proteins with co-factors 
and substrates. 
Extensive crystallization trials failed to yield diffracting crystals of METTL2, 
6, or 8 proteins, with only some low quality crystals/ precipitates obtained, as 
shown in Figure 4-4 (D). This growth conditions generate low quality crystals 
no good diffraction data is obtained. Current NMR is unable to study the 
proteins at the size range of METTL2, 6, 8, while cryo-EM could only solve 
higher molecular weight proteins at this moment. 
METTL2, 6, 8 has been predicted to contain a large portion of disordered 
region at N- terminal by XtalPred (174). Without any new strategy, it would 
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be quite difficult to crystallize human METTL2 alone (or other METTL 
proteins). Growing co-crystal complex between METTL2, co-factor SAM or 
SAH, and threonine tRNAs may have the possibility  to stabilize the disorder 
issue in METTL2 proteins. There are several studies in which a series of 
mutation are introduced to reduce the entropy of surface exposed residues. 
Those mutations have successfully helped in protein crystallizations (or called 
surface entropy reduction, SER strategy) (204). In particular, a mutation of 3 
residues, K100A, E101A, E103A helped obtained the crystal structure of 
human nicotinamide N-methyltransferase (hNNMT) (205), which is relatively 
close to METTl2, 6, 8 proteins by sequence alignment. 
As shown in Figure 4-4(A) and (B), Seryl-tRNA synthetase of 
T.Thermophilus in complex with a part of tRNASer has been solved, without 
residue at position 32. While only apo structure of human SARS has been 
solved, without tRNA substrates. In sum, no crystals structures for tRNAs 
with m3C at position 32 has been solved. Once solved, it would provide 
insights into potential functions of this modifications at this position.  
Alternatively, a co-crystal structure between METTL2, with tRNA, or together 
with corresponding aminoacyl-tRNA synthetase would be another possibility 
to grow out crystals and to study at functions of 3-methylcytosine. As shown 





Figure 4-4 Seryl-tRNA synthetase structures of T.Thermophilus and homo 
sapiens 
(A) Seryl-tRNA synthetase of T.Thermophilus in complex with tRNASer 
(PDB: 1SER), With tRNA phosphate sugar backbone in orange and bases in in 
blue; two subunits of SARS are shown in Green and Red, respectively, Figures 
are made by Pymol;(notice the incomplete tRNA molecules) 
(B) Human SARS structure without tRNA, (PDB: 4L87), Adapted from (172). 
(C) Proposed interaction model for METTL6 and SARS. The two alpha helix 
arelocated at the N-terminal of SARS. 
(D) Some small crystals and many precipitates have been observed in one 
buffer condition screened. 
 
 
4.9 Future work on m3C and codon biased translation 
3-methylcytosine has been proposed to have a role in codon biased translation 
for certain stress related transcripts (117) 
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In order to take a glimpse of threonine codon percentage in human 
transcriptome, and prepare for further ribosome profiling analysis. Codon 
percentage across human transcriptome is calculated. In short, ref_seq mRNAs 
were downloaded from USCS, excluding 5’ UTR and 3’ UTR. Then codon 
counting for each mRNA for each 61 codons (excluding stop codons) were 
calculated using Python scripts as written below and analysed using Excel. 
Each ref_seq entry was ranked by percentage of one of the codons, thus a 
codon percentage ranking for each 61 codons were generated. The Python 
scripts are presented in section 2.21, and Threonine codon percentage Ranking 
is presented Table 4-1.  
In general, the membrane proteins, such as mucin family proteins has the 
highest threonine percentage. It is similar to the date from yeast(117). Of note,  





1 33.65 NM_001198815 mucin 22 (MUC22) 
2 24.05 NM_001040105 mucin 17, cell surface associated 
3 23.94 NM_005960 mucin 3A 
4 22.36 NM_001164462 mucin 12, cell surface 
associated; similar to mucin 11 
5 21.64 NM_001127710 proteoglycan 4 
6 21.11 NM_001127709 proteoglycan 4 
7 20.98 NM_002458 mucin 5B, oligomeric mucus/gel-
forming 
8 20.78 NM_001303232 proteoglycan 4 (PRG4), 
transcript variant E 
9 20.67 NM_001127708 proteoglycan 4 
10 20.21 NM_005807 proteoglycan 4 
11 19.4 NM_018406 mucin 4, cell surface associated 
12 19.22 NM_001010909 mucin 21, cell surface associated 
13 18.67 NM_080870 diffuse panbronchiolitis critical 
region 1 
14 18.66 NM_001010909 mucin 21, cell surface associated 
15 18.6 NM_001129895 similar to HGC6.3 




17 18.08 NM_012206 hepatitis A virus cellular receptor 
1 
18 18.08 NM_001173393 hepatitis A virus cellular receptor 
1, transcript variant 3 
19 17.72 NM_024690 mucin 16, cell surface associated 
20 17.66 NM_001308156 hepatitis A virus cellular receptor 
1 
21 17.58 NM_058173 mucin-like 1 
22 17.22 NM_182832 placenta-specific 4 
23 17.11 NM_022338 chromosome 11 open reading 
frame 24 
24 16.93 NM_005961 mucin 6, oligomeric mucus/gel-
forming 
25 16.84 NM_001142403 CD164 molecule, sialomucin 
26 16.75 NM_052932 transmembrane protein 123 
27 16.57 NM_001080400 KIAA1881 
28 16.46 NM_001142404 CD164 molecule, sialomucin 
29 16.4 NM_001145006 mucin 7, secreted 
30 16.22 NM_003006 selectin P ligand 
31 16.16 NM_006016 CD164 molecule, sialomucin 
32 16.03 NM_016242 endomucin 
 
Importantly, three threonine codons: ACA, ACT, ACC’s rankings follows a 
similar pattern to total threonine codons as in Table 4-1. However, ACG, 
codon specific ranking did not show a similar enrichment, the highest mRNA 
which harbors ACG codons only has about 5.5 % percentage and they are no 
longer mucin family proteins and the ranking is shown in Appendices 3.  
4.10 Models for m3C in translation and other cellular process 
According to the literature review and results obtained so far, Figure 4-5 is 
drawn to show proposed important future work to perform, Table 4-2 Table 
4-2 Potential functions of 3-methylcytosine in various Cellular processeslisted 
several potential functions and proposed assays for studying 3-methylcytosine 




Figure 4-5 Model for possible roles of METTL2 in tRNA modification and 
translation  
Loss of METTL2, 6, 8 may also affect ribosomal interaction with certain 
tRNA contains m3C (or m2, 2G), which is being further characterized by 
ribosomal profiling and proteomics. Loss of m3C may also affect tRNA 
stability, which should be studied by Northern blot. 
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Name Brief comments 
1 
376 pPyCAGIP-Flag-Mettl2-Myc Overexpression in mammalian 
cell lines 
2 377 pPyCAGIP-Flag-Mettl2-T2A-EGFP Same  
3 378 pPyCAGIP-Flag-hMettl2-T2A-EGFP Same 
4 497 pEF6-Flag-hMettl2-myc Expression good in western, 
mutation? 5 528 pPyCAGIP-Flag-Mettl2 no myc tag at C terminal 
6 683 pEYFPC1-hMettl2A mettl2A 
7 686 pPyCAGIP-Flag-hMettl2A-T2A-EGFP mettl2A 
8 688 pPyCAGIP-Flag-hMettl2A-T2A-mCherry mettl2A 
9 756 pPYCAGIP-Flag-hMettl2A-∆SAM-T2A-
EGFP 
27nt deletion in SAM binding 
motif 10 519 pPyCAGIP-Flag-Mettl2-∆SAM-Myc 27nt deletion in SAM binding 
motif 11 529 pPyCAGIP-Flag-Mettl2∆SAM no myc tag at C terminal 
12 691 pEYFPC1-hMettl2-∆SAM    
13 520 pPyCAGIP-Flag-Mettl2-G3A-Myc Three glycine to Alanine 
mutation, extra mutation 
found 
14 530 pPyCAGIP-Flag-Mettl2G3A no myc tag at C terminal 
15 534 pPyCAGIP-GST-Mettl2-G3A-Myc GST tag 
16 995 pTRE3G-Flag-hM2B-IRES-EGFP BamHI/NdeI 
17 996 pTRE3G-Flag-hM2-IRES-EGFP-BSD   
18 997 pTRE3G-Flag-hM2-∆SAM-IRES-EGFP-
BSD 







21 1025 pPyCAGIP-GST-hSARS-1-72 SARS truncations 
22 1026 pPyCAGIP-GST-hSARS-1-152 
23 1027 pPyCAGIP-GST-hSARS-1-514 
24 1028 pPyCAGIP-GST-hSARS-153-460 
25 1029 pPyCAGIP-GST-hSARS-153-514 




27 375 pET15b-mMettl2  His tag purification mouse 
METTL2 28 498 pGEX6P1-Mettl2 mouse ∆SAM SAM motif 27ny deleted 
29 499 pGEX6P1-Mettl2 mouse G3A extra mutation just before 
G3A;  30 856 pFASTB-Hta-huMettl2A human 
31 857 pFASTB-Hta-huMettl2A-∆SAM human 
32 858 pET15b-huMettl2A human 
33 859 pET15b-huMettl2A-∆SAM human 
34 1002 pet15b-hMettl2-G3A-Mutation Very good 3 mutation 
35 1003 pet15b-hMettl2-G3A-Mutation backup Very good 3 mutation 
36 1004 pet15b-hMettl2-insertion   
37 1050 pET21b-huSARS His tag at C-Terminal 
38 413 pLVx-puro-mettl2 mouse shRNA1   
39 414 pLVx-puro-mettl2 human shRNA1 1054nt on CDS 
40 561 pLVx-GFP-hMettl2 shRNA1 GFP version 
41 562 pLVx-GFP-hMettl2 shRNA2   
42 563 pLVx-puro-Mettl2 shRNA3 target elsewhere 
43 564 pLVx-GFP-Mettl2 shRNA3 target elsewhere 
44 636 pLVx-GFP-hMettl2 shRNA1 missing, LA 
45 637 pLVx-GFP-hMettl2 shRNA1   
46 638 pLVx-puro-Mettl2-3'UTR-shRNA1   
47 680 pLKO puro scramble   
48 786 pLKO-puro-mettl2-shRNA1 3UTR 
49 787 pLKO-puro-mettl2-shRNA2 CDS 
50 788 pLKO-puro-mettl2-shRNA3 CDS 
51 789 pLKO-puro-mettl2-shRNA4 CDS 
52 790 pLKO-puro-mettl2-shRNA5 3UTR 
53 791 pLKO-puro-hMettl2A-shRNA1 3UTR 
54 792 pLKO-puro-hMettl2A-shRNA2 CDS, unique on 2A, Same as 
414 55 793 pLKO-puro-hMettl2B-shRNA3 CDS 
56 794 pLKO-puro-hMettl2B-shRNA4 CDS 
57 795 pLKO-puro-hMettl2B-shRNA5 3UTR unique on 2B 
58 807 pST1374-NLS-flag-linker-Cas9 Xingxu Huang lab 
160 
 
59 854 MLM3636-huMettl2-1   
60 855 MLM3636-huMettl2-2   
61 860 MLM3636-Mettl6-Cas9-F1+R1 Mouse M6 gRNA 
62 861 MLM3636-Mettl6-Cas9-F2+R2   
63 932 MLM3636-TRM1 gRNA1 work with Mettl2 together to 
see translation 64 933 MLM3636-TRM1L gRNA1 work with Mettl2 together to 
see translation 65 936  pSpCas9(BB)-2A-GFP (PX458) from DAI, GIS  
66 937 pLKO-TRMT1 shRNA1   
67 938 pLKO-TRMT1 shRNA2   
68 939 pLKO-TRMT1-like shRNA1   
69 940 pLKO-TRMT1-like shRNA2   
70 946 pRGEN_Cas9-HA_CMV expression vector Toolgen Korean 
71 947 pRGEN_Mm-Mettl8_U6_SG_1 mouse M8 gRNA1 
72 948 pRGEN_Mm-Mettl8_U6_SG_2 mouse M8 gRNA2 
73 1055 pST1374-NLS-flag-linker-Cas9 D10A Cas9 Nickase  
74 1016 pEF6-Rluc-SerUCA5-Luc2   
75 1017 pEF6-Rluc-SerUCG5-Luc2   
76 1019 pEF6-Rluc-Luc2 For Codon Reporter 
77 1020 pcDNA3.1-Rluc-Luc2 For Codon Reporter 
78 1034 pEF6-Rluc-SerAGU5-Luc2   
79 1035 pEF6-Rluc-SerUCG10-Luc2   
80 1036 pEF6-Rluc-GScodon5-Luc2   
81 1037 pEF6-Rluc-CodonRunCtrl-Luc2   
82 1042 pEF6-Rluc  No Luc2 
83 1101 pEF6-Rluc-ThrACA10-Luc2   
84 1102 pEF6-Rluc-ThrACT10-Luc2   
85 1103 pEF6-Rluc-ThrACC10-Luc2   
86 1104 pEF6-Rluc-ThrACG10-Luc2   
 
Appendix 2. Primers excluding those listed in Materials and Methods 













map to hMettl2A&B cDNA start with kozak, 
ATG, KpnI in overhang  
hM2_cDNA_F4 acgcGTCGACtcGCCGGCTC
CTACCCTGAAGGTG 
map to hMettl2A&B cDNA start without 
ATG, SalI in overhang, tc added to avoid 




map to human mettl2B cDNA end without 




map to human mettl2B cDNA end without 





map to human mettl2A cDNA end with stop 




map to human mettl2A cDNA end with stop 
codon,  (mettl2b has TAA as stop 
codon)XbaI in overhang 
 











ACACTG M2_dSANT_R T CTT AAAAACCCATTTTCATGCCAGGCATTGTGATGG
AAGACGCGC hM8_dSAM_F2 acccttttccagatgggatcGTCTTTGTGCTCTCTTCTATTCATCCTG 
hM8_dSAM_R2 gaatagaagagagcacaaagacGATCCCATCTGGAAAAGGGTAAGG 
hMettl2 U6 F1 ACACCCTGCAATCCTCGCCGATAAGG 
hMettl2 U6 R1 AAAACCTTATCGGCGAGGATTGCAGG 
hMettl2 U6 F2 ACACCTGCACCTTCAGGGTAGGAGCG 
hMettl2 U6 R2 AAAACGCTCCTACCCTGAAGGTGCAG 
hM2_gRNA1_F_seq GACTCCGCGTCTTCTGAAAGAG 
hM2_gRNA1_R_seq GCTTTTCGGAGTGCTCCGAG 
hTRMT1 U6 F1 ACACCGCTGCCGAATACAGCAGCGAG 
hTRMT1 U6 R1 AAAACTCGCTGCTGTATTCGGCAGCG 
hTRMT1L U6 F1 ACACCGGAGCTGCTGCCCCTGGAGAG 
hTRMT1L U6 R1 AAAACTCTCCAGGGGCAGCAGCTCCG 
 













GAPDH (human) ACCGTCAAGGCTGAGAACGGGA 
GAPDH (human) CCCTGCAAATGAGCCCCAGCC 
GAPDH (mouse) GGTTGTCTCCTGCGACTTCAACAGC 
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Appendix 2.4 Oligos for making Codon Runs 























 *Nucleotide in Bold indicates restriction sites overhangs 
Appendix 3 Top mRNAs with threonine ACG codon percentage content 
>3.9 % in human 
 ACG % Ref_seq Accession  
1 5.56 NM_000442 platelet/endothelial cell adhesion molecule 
2 5.26 NM_017914 chromosome 19 open reading frame 24 
3 4.92 NM_001272007 iron-sulfur cluster assembly 2 
4 4.82 NM_206833 cortexin 1 
5 4.66 NM_001099414 hepatitis A virus cellular receptor 1 
6 4.66 NM_012206 hepatitis A virus cellular receptor 1 
7 4.66 NM_001173393 hepatitis A virus cellular receptor 1 
8 4.48 NM_001080457 leucine rich repeat containing 4B 
9 4.44 NM_021103 thymosin beta 10 
10 4.44 NM_021109 thymosin-like 2 (pseudogene); thymosin-like 




12 4.39 NM_001078173 family with sequence similarity 127, member 
C; hypothetical LOC100128949 13 4.39 NM_001078172 family with sequence similarity 127, member 
B 14 4.29 NM_153200 endothelial differentiation-related factor 1 
15 4.26 NM_005663 Wolf-Hirschhorn syndrome candidate 2 
16 4.23 NM_001281297 endothelial differentiation-related factor 1 
17 4.23 NM_033258 guanine nucleotide binding protein (G 
protein), gamma 8 18 4.10 NM_001267558 r grammed cell death 6 
19 4.09 NM_016643 zinc finger protein 771 
20 4.09 NM_001142305 zinc finger protein 771 
21 4.08 NM_000997 ribosomal protein L37 
22 4.03 NM_003792 endothelial differentiation-related factor 1 
23 4.00 NM_020412 chromatin modifying protein 1B 
24 3.97 NM_015381 family with sequence similarity 19 
(chemokine (C-C motif)-like), member A5 25 3.92 NM_198708 hydroxysteroid (11-beta) dehydrog nase 1-
like 26 3.92 NM_001145250 solute carrier family 29 (nucleoside 
transporters), member 3; Sp9 transcription 
factor homolog (mouse) 
 
